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1   Abstract 
Nucleic acid-based molecules have certain advantages over conventional drugs or 
protein-based target approaches. Chemically synthetized nucleic acids-based 
molecules are known as aptamers. They are selected from a combinatorial 
oligonucleotide library in a unique way called ―SELEX‖ (systematic evolution of 
ligands by exponential enrichment). These are single-stranded oligonucleotides with 
specific three-dimensional configuration.  They can be bound to their specific target 
with high affinity and specificity. Recently, aptamers targeting mammalian cells have 
emerged as potential candidates for use as delivery vehicles. Numerous therapeutic 
agents including miRNA, siRNA, peptides, proteins, nanoparticles, and 
chemotherapeutics can be delivered into the cells via cell-targeting aptamers.  
 
Macrophages and dendritic cells (DCs) play a vital role in the immune response. 
These cells are involved in physiological and pathological processes in the body. 
DCs are considered to be one of the most potent ―professional‖ antigen presenting 
cells (APCs) and have the properties to present endogenous or foreign antigens on 
their surfaces for the activation of T cells. Therefore, DC-based vaccines designed 
for activation and proliferation of T cells have significant immunotherapy-related 
importance. On the other side, macrophages play a key role in different diseases 
including chronic inflammation. miRNA 125a-5p is highly upregulated in chronic 
inflammatory macrophages and may have an impact on the polarization of 
macrophages or on the condition of the disease. 
 
In the current study, it was explored that an aptamer targeting immune cells could be 
used as a delivery vehicle. Herein, Next generation sequencing (NGS) data of 
murine bone marrow-derived DCs cell-SELEX was used to identify a promising 
aptamer targeting macrophages and DCs. DC 12 aptamer has been identified and 
characterized as a promising and suitable delivery vehicle. It has been shown that 
DC 12 aptamer is non-immunogenic and internalizes into the cells.  
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The study found that DC 12 aptamer guided uptake of antagomir 125a-5p may end 
up in the endosomal compartment of macrophages, thereby limiting its inhibitory 
effect. However, DC 12 has the potential to deliver OT-I peptide into the desired 
processing compartment of BM-DCs for the targeted activation of CD8 T cells. In 
summary, aptamers have the potential to replace other carrier molecules, but further 
investigation will be needed as regards the delivery of the cargo into the cell 
cytoplasm. 
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2   Zusammenfassung 
Moleküle auf Nukleinsäurebasis haben gewisse Vorteile gegenüber konventionellen 
Medikamenten oder protein-basierenden Zielansätzen. Chemisch synthetisierte, auf 
Nukleinsäuren basierende Moleküle werden als Aptamere bezeichnet. Die Selektion 
von Aptameren aus einer kombinatorischen Oligonukleotid Bibliothek wird als 
SELEX (systematicevolutionofligandsbyexponentialenrichment) genannt. Aptamere 
sind einzelsträngigeOligonukleotide mit einer spezifischen drei-dimensionalen 
Struktur, welche in der Lage sind ihr Zielmolekül mit hoher Affinität und Spezifität zu 
binden. Kürzlich haben sich Aptamere, die an Säugetierzellen binden, als potenzielle 
Liefermoleküle erwiesen. Zahlreiche therapeutische Wirkstoffe wie miRNA, siRNA, 
Peptide, Proteine, Nanopartikel und Chemotherapeutika können über zellspezifische 
Aptamere in die Zellen transportiert werden. 
 
Makrophagen und Dendritische Zellen (DCs) spielen eine zentrale Rolle in der 
Immunabwehr. Diese Zellen sind in physiologischen und pathologischen Prozessen 
involviert. DCs werden als eine der wirksamsten „professionellen― 
antigenpräsentierenden Zellen (APCs) angesehen, die die Eigenschaft besitzen 
endogene und fremde Antigene auf der Zelloberfläche zu präsentieren um T-Zellen 
zu aktivieren. Daher sind Impfstoffe basierend auf dendritische Zellen, die zur 
Aktivierung und Proliferation von T-Zellen beitragen, von immunotherapeutischer 
Relevanz. Andererseits spielen Makrophagen eine Schlüsselrolle in verschieden 
Krankheiten wie zum Beispiel chronischen Entzündungen. Die Expression von 
miRNA 125a-5p ist in chronisch entzündlichen Makrophagen stark überexprimiert, 
welche eventuell einen Einfluss auf die Polarisierung der Makrophagen oder die 
Ausprägung der Krankheit haben kann. 
 
In der nachfolgenden Studie wurde untersucht, ob einAptamer, das an Immunzellen 
bindet, als Liefermolekülgenutzt werden könnte. Dabei wurden Daten 
des„nextgenerationsequencing― (NGS) von der aus murinem Knochenmark 
gewonnenen DCs Zell-SELEX verwendet, um Aptamere zu finden, die an 
Zusammenfassung 
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Makrophagen und DCs binden. Das Aptamer DC 12 wurde identifiziert und als 
vielversprechendes und geeignetes Liefermolekül charakterisiert. Es konnte gezeigt 
werden, dass DC 12 nicht immunogen ist und von den Zellen internalisiert wird.  
 
In der Studie konnte außerdem gezeigt werden, dass die von DC 12 gesteuerte 
Aufnahme von Antagomir 125a-5p im endosomalen Kompartment der Makrophagen 
enden könnte und somit den inhibitorischen Effekt limitiert. Allerdings hat DC 12 das 
Potential OT-I Peptide in die entsprechenden Kompartimente von BM-DCs für die 
gezielte Aktivierung von CD8 T-Zellen zu transportieren. Zusammenfassend haben 
Aptamere das Potential andere Transportmoleküle zu ersetzen, jedoch sind weitere 
Studien nötig in Bezug auf die Lieferung des Frachtmoleküls in das Zytoplasma der 
Zelle. 
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3   Introduction 
3.1   Aptamers 
Nucleic acid-based molecules, known as aptamers, are ssDNA or RNA that have 
well defined three-dimensional configurations1 (Figure 3.1.1). They exhibit a high 
specificity and affinity for their targets including small molecules, extracellular 
proteins, enzymes, peptides, and even for the whole cell. These properties are 
based on several types of interactions such as complementarity shape, van der 
Waals forces, base stacking, hydrogen bonding, hydrophobic, and electrostatic 
interactions2. 
 
Figure 3.1.1: Schematic illustration of the ssDNA or RNA aptamer binding to the target depending on the 
three-dimensional configuration of the aptamer. ssDNA or RNA aptamer folds into a 3D structure, upon which 
it interacts with the target (e.g., small molecules, peptides, and cells etc)
3
.  
 
3.1.1   Selection method of aptamers 
Aptamers are selected from the ssDNA or RNA library followed by a process known 
as SELEX4. This selection method was introduced by three independent groups; 
Szostak & Ellington, Gold & Tuerk, and Robertson & Joyce groups in the 1990‘s5-7. 
The selection procedure starts with the incubation of the starting library of 1014 to 
1015 random sequences with the target of interest. The random sequence is flanked 
by constant primer binding sites on both sides of the sequence to allow PCR 
Introduction 
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(polymerase chain reaction) amplification. After incubation, the target-bound 
sequences are isolated from the unattached or weakly bound sequences. The 
isolation process is either facilitated by immobilizing of the respective target on the 
matrix or by the unattached and weekly bound sequences are separated by flow 
cytometry, electrophoresis or centrifugation8-10. The target bound sequences are 
amplified by PCR after decoupling from the target of interest. Single-stranded 
sequences are generated from amplified PCR products that are further used for the 
next rounds of SELEX. In general, 8-10 cycles of SELEX are needed to find the 
most promising candidate sequence, which binds with high affinity and 
specificity11,12. The promising candidate sequences are sequenced and synthesized 
using solid phase synthesis for further characterization.  
 
3.1.2   Selection method for cell-targeting aptamers 
In order to identify the whole cells-targeting aptamers, both prokaryotic and 
eukaryotic cells can be used without the preliminary knowledge of the putative target 
molecule on the cell surface13. Morris et al.14 described the cell-based SELEX 
methodology (cell-SELEX) for the first time, using a complex mixture of human red 
blood cell membrane targets. The main advantage of the cell-SELEX is that the 
target proteins are naturally folded and native state to the cell surface15. Aptamers 
have been selected against different types of cancer cells16 and also against live 
pathogens such as viruses17 and bacteria18. Cell-SELEX based selection usually 
involves both positive and negative selection (Figure 3.1.2). The positive selection is 
used to identify the aptamers that are specific to target the positive cells while 
negative selection is used to eliminate nonspecific sequences that bind negative 
cells. The target of interest can be expressed naturally, as in various diseases, or 
overexpressed on the surface of the cells. Negative cells must be unrelated to 
positive cells in terms of target expression in order to remove non-specific 
sequences from the library19. Cell-SELEX can generate a variety of aptamers that 
can differentiate between different cancer cells or between cancer cells and normal 
cells13. 
Introduction 
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Figure 3.1.2: Schematic illustration of the cell-SELEX process 
Cell-SELEX is performed to obtain cell-targeting aptamers for different applications. In general, the 
oligonucleotide library of 10
14 
to 10
15 
random sequences is incubated with the cells (1), the sequences 
bound to the target are dissociated from the unbound sequences (2), dissociation of target-bound 
sequences from the target (3), incubation with the negative cells (4), unbound sequences are retained 
(5), amplified (6), single strand digestion of PCR product (7), and used in the next selection cycle (8). 
 
3.1.3   Cell-targeting aptamers 
Cell-targeting aptamers have certain advantages over other targeting molecules 
such as antibodies as they are small in size and easy to synthesize20. Aptamers are 
chemically synthesized due to which they are also termed as ―chemical antibodies‖ 
and their functional properties are also similar to antibodies. For example, epithelial 
cell adhesion molecule (EpCAM) aptamer has been shown to be more promising 
agent for targeting cancer cells and molecular imaging compared to the EpCAM 
antibody21.  
 
After the selection procedure, aptamers can be chemically modified to overcome 
their limitations such as short half-life and nuclease degradation. Polyethylene glycol 
(PEG) and the introduction of chemical modifications e.g., 2′-fluoropyrimidines, 2′-O-
methyl ribose purines, and 2′-amino pyrimidines alters the overall pharmacokinetic 
profile and minimize the attack from the nucleases, respectively22,23. 
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Another of the most promising features of cell-targeting aptamers is their ability to 
internalize into the respective cells after binding24. These aptamers can be used as a 
delivery vehicle for delivery of cargo molecules such as proteins, nucleic acids, 
nanoparticles, and drugs25-29 (Figure 3.1.3). 
 
Figure 3.1.3: Schematic presentation of cell-targeting aptamers as a delivery tool 
Different cargo molecules can be coupled to the cell-targeting aptamers for delivery into the cells 
(modified from Mayer et al.
30
). 
 
Furthermore, a few cell-targeting aptamers used for the delivery of cargo molecules 
(nucleic acids) e.g., miRNA, anti-miRNA, and siRNA are listed below (Table 3-1). 
Table 3-1 Cell-targeting aptamers delivered cargo nucleic acids 
 
Aptamer Type Targeted cell/model Cargo nucleic acid 
GL21.T
31
 RNA A549 miRNA212 
GL21.T
32
 RNA A549 let-7g miRNA 
A 10
33
 RNA Prostate cancer tumor model siRNA 
A10.32
34
 RNA LNCaP miRNA 15a, miRNA-16-1 
AptNCL
35
 DNA CL1-5 siRNA 
EpAPT
36
 RNA WERI-Rb1 and MCF7 cell lines siRNA 
AS1411
28
 DNA MCF-7 Anti-miRNA 21 
MUC1
37
 DNA Xenograft tumor models miRNA-29b 
TRA
38
 RNA HUVEC miRNA-126 
HER2, HER3
39
 RNA HER2+ Breast cancer siRNA 
DNA aptamer
40
 DNA T-cells siRNA 
Introduction 
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3.1.4   Aptamers targeting immune cells as a delivery 
vehicle 
As described above, the cell-targeting aptamers have a number of advantages. They 
have the ability to recognize target proteins in their native states and according to 
the expression level of the target on the cell surface15,19. Until then, the different 
molecules involved in the immune system have been targeted by aptamers and are 
capable of altering the immune reaction. The important role of aptamers can be 
explored as a new pharmacological agent in the diagnostic and therapeutic tool for 
immune diseases41.  
 
The main challenges in immune modulation or therapy can be addressed by 
aptamers. The three main challenges are; to increase tumor immunogenicity, inhibit 
immunosuppressive mechanisms, and activate immune receptors42. Therefore, 
aptamers targeting immune cells (monocytes, DCs, and macrophages) could be 
suitable for modulating the immune response in different diseases. Immune cell-
targeting aptamers could be used as an agonist or antagonist to specific receptors, 
identification of biomarkers for immune specific disorders or as a delivery vehicle. In 
this study, an aptamer targeting immune cells was characterized and used as a 
delivery vehicle. 
 
Berezhnoy et al.43 have shown that aptamer conjugated with siRNA has the ability to 
target CD8+ T cells and induce vaccine-mediated memory and antitumor effect. The 
aptamer was designed to target 4-1BB, the major costimulatory receptor on the 
surface of activated T cells44. Song et al.45 described that CD4 aptamer has the 
potential to deliver siRNA by targeting CD4+ human T cells. Thus, an aptamer 
targeting immune cells could be a promising tool to be used as delivery of cargo 
molecules for immune disorders.  
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3.2   The mononuclear phagocyte system (MPS) 
The mononuclear phagocyte system is a well-defined group of cells comprising of 
DCs, monocytes, and macrophages, whereas, monocytes are the major type of 
MPS in the blood. Macrophages and DCs have the same functional properties and 
the latter are potent professional APCs46-48. 
 
The origin of macrophages, DCs, and monocytes originate from two types of 
progenitors in the bone marrow; the common DC progenitor (CDP) and monocyte & 
DC progenitor (MDP).  MDP can give rise to monocytes and DCs, but CDP is 
specific to DCs only49,50. 
 
3.2.1   Monocytes 
Members of the mononuclear phagocyte system, monocytes, play a significant role 
in immune defense, homeostasis, and inflammation. These are bone-marrow 
derived leukocytes that are released and circulated in spleen and blood. They have 
the characteristic property of sensing ―danger signals‖ through pattern recognition 
receptors51. These cells have the ability for phagocytosis, antigens presentation, 
secretion of chemokines, proliferation, and initiate adaptive immunity51,52. Monocytes 
are also considered as progenitor pool because of their ability to differentiate 
between macrophages and DCs51,52. 
  
3.2.1.1   Monocytes subsets 
During circulation in the blood, monocytes are considered to be a flexible and 
dynamic cell population consisting of different subsets. They differ in their 
phenotype, morphology, size, and transcriptional profiles depending to their location 
in the blood53. In humans, CD14 and CD16 surface marker expression and in mice 
LY6C, CCR2, and CX3CR1 markers could be used to distinguish between different 
subset populations54 (Figure 3.2.1). CD14+ and CD16- monocytes are considered as 
classical monocytes which make up to ~85% of the circulating pool whereas 15% 
Introduction 
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consists of intermediate monocytes (CD14+CD16+) and nonclassical monocytes 
(CD14loCD16+) in humans53,55 (Figure 3.2.1). Likewise, in the mice, two discrete 
monocyte subsets have been described, classical monocytes 
(LY6ChiCCR2+CX3CR1
int) and non-classical monocytes (LY6CloCCR2-CX3CR1
hi)53,56 
(Figure 3.2.1).  
 
Figure 3.2.1: Human monocytes are classified into three subsets depending on the expression level 
of CD14 and CD16: classical (CD14
+
CD16
-
), intermediate (CD14
+
CD16
+
), and non-classical 
(CD14
lo
CD16
+
) monocytes. Mice equivalent subsets have different expression levels of LY6C, CCR2, 
and CX3CR: classical (LY6C
hi
CCR2
+
CX3CR
int
), intermediate (LY6C
int
CCR2
+
CX3CR
+
), and non-
classical (LY6C
lo
CCR2
-
CX3CR
hi
) monocytes
53-56
. 
 
―Classical monocytes‖ have upregulated chemokine receptor CCR2 (Figure 3.2.1) 
and may be recruited at the site of infection or injury and differentiated into 
inflammatory macrophages, in mice56,57. They are known as inflammatory mediators 
and are the most abundant subset population recognized in atherosclerotic 
plaques58. 
―Non-classical monocytes‖ are also known as patrolling monocytes because they 
continuously patrol the luminal side of the vascular endothelium and clean the 
debris59,60.  
―Intermediate monocytes‖ are generally have inflammatory characteristics, but have 
high expression of CX3CR1 adhesion-related receptors. These monocytes are 
different from the other subsets and do not participate in patrolling of vascular 
endothelium61,62. 
 
Monocytes are considered to be the main component of the mononuclear phagocyte 
system. They are also known as the natural reservoir of macrophages and DCs. The 
Introduction 
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majority of macrophages have been found in tissues, including vital organs. DCs are 
well known and most efficient APCs of the mononuclear phagocyte system63. 
 
3.2.2   Dendritic cells  
These cells were described by Steinman and Cohn64, regard to the establishment of 
the connection between innate and adaptive immunity65,66. They are the most 
efficient and powerful APCs with distinctive properties to activate naïve T-cells67. In 
the innate immune system, DCs usually recognize pathogen-associated molecular 
patterns (PAMPs), damage-associated molecular patterns (DAMPs), and release 
protective cytokines66,68. In the acquired immune system, they mostly act as APCs 
by antigen uptake, processing, and presenting of harmful molecules and antigens. 
Thus, play an important role in the initiation of adaptive immunity66.  
 
3.2.2.1   Dendritic cells subsets 
DCs are divided mainly into two subsets, plasmacytoid DCs (pDCs) and 
conventional/classical DCs (cDCs)66,69. The pDCs have a different life cycle than the 
cDCs but the origin of both subsets are similar. pDCs are mainly reside in the blood 
and lymphoid tissues. They enter the lymph nodes through blood circulation. They 
have low expression levels of major histocompatibility class II (MHC II), 
costimulatory molecules, and integrin CD11c in the steady state70. These cells are 
the major effector cells in the innate immune response after viral infection due to 
their powerful capability to release type I interferons (IFN). In the immature state, 
these cells could be involved in tolerance (immune suppression)71. 
 
All DCs other than pDCs are considered to be cDCs. cDCs are a small subset of 
tissue hematopoietic cells that reside in the lymphoid and non-lymphoid tissues. 
These cells have a powerful ability to recognize tissue damage, trap or engulf 
environmental, and cell-associated antigens, process and present these engulfed 
antigens to activate T lymphocytes. Thus, the cDCs have the property to induce 
immunity to any exogenous antigens and to impose tolerance to endogenous 
Introduction 
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antigens70. Bacterial molecules are also sensed by cDCs, which results in the 
release of certain cytokines, including proinflammatory cytokines (TNF-α and 
interleukin-6) and interleukin-12p70 (IL-12p70) for the activation of T cell subsets 
(Th1 and Th17). These cells are therefore able to recruit cytotoxic T cells (CTLs)66,69. 
 
3.2.2.2   Recognition, capture, processing, and 
presentation of the antigens 
PAMPs are recognized by immature DCs, including microbial lipids, nucleic acids, 
intermediates of viral proteins, and carbohydrates through pattern recognition 
receptors (PRRs). Different PRRs could be involved in the pathogen recognition 
processes, such as Toll-like receptor (TLR), RIG-I-like helicases, C-type lectin 
receptors (CLRs), active protein kinase (PKR), and nucleotide-binding 
oligomerization domain (NOD-like) receptors66,71. 
 
Once PAMPs are recognized, DCs can capture or engulf the antigen through 
different mechanisms such as endocytosis, macropinocytosis, and receptor-
mediated phagocytosis58,72,73. Particles and microbes are taken up by the DCs 
through phagocytosis. Macropinocytosis refers to the process by which extracellular 
fluid and solutes are taken after the formation of large pinocytic vesicles. DCs 
express different types of receptors that facilitate the process of endocytosis, such 
as C-type lectin receptors like the macrophage mannose receptor, epithelial 
cell receptor 205 kDa (DEC-205), and Fc receptors65. Once the antigen is captured, 
it is delivered to the antigen processing compartments71.  
 
DCs process proteins and degraded them into antigenic peptides that are loaded on 
the major histocompatibility complex (MHC), either MHC class I (MHC I) or class II 
(MHC II) molecules69,72. Whereas, the process of the lipids molecules is different and 
they are loaded onto non-classical MHC molecules72. 
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DCs present antigens after processing in three different ways: 
 
1. MHC I to CD8 T cells: Intracellular antigens (endogenous peptides) are 
loaded to the cell surface of MHC class I molecules and are recognized by 
the CD8 T cells. For example, if a cell is infected with a virus, viral peptides 
are processed and presented by DCs. It allows the immune system to detect 
and activate CD8 T cells to kill the infected cells69,74.  
 
2. MHC II to CD4 T cells: The exogenous peptides are loaded on MHC class II 
and activate CD4 T cells. They are derived from the proteins that are 
endocytosed and then degraded by acid-dependent proteases in the 
endosomes69,74. 
 
3. Cross-presentation: An important feature of DCs is cross-presentation, 
mainly of specific subsets of DCs including CD8 DCs and migratory CD13 
DCs75. It consists of presenting exogenous antigens on MHC class I 
molecules and has been involved in the stimulation of CD8 T cells69,74,75.  
 
3.2.2.3   DCs as a therapeutic target 
The distinctive family of professional APCs known as DCs is able to induce and 
regulate immune responses when they come into contact with the antigens7676,77. 
Since the 1990s, different protocols for in vitro culture of the human and mouse DCs 
have been studied which have helped to understand the biology of DCs78. DCs play 
a very important role in linking the innate and adaptive immune response. These 
features have made them an appropriate therapeutic target for immunotherapy. 
Various attempts have been made and are currently under study to develop DC-
based vaccines. These vaccines can be considered as preventive or therapeutic 
vaccines for the treatment of cancer. The main purpose of the preventive vaccines is 
to prevent immune memory diseases, while the therapeutic vaccines target existing 
cancer cells by inducing an immune response79,80. 
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These vaccines generally contain DCs loaded with the tumor antigens, for initiation 
and regulation of an immune responses in cancer patients.  These DC-based 
vaccines are also used in the development of different immunotherapies against 
autoimmune disorders, infectious diseases, and cancer (all of these which requires T 
cell-mediated immunity)81. Generally, DC-based vaccines are primarily classified into 
two categories: ex vivo antigen-loaded DC-based vaccines and in vivo, DC-targeted 
vaccines81,82.  
 
Ex vivo DCs are generated from the BM-progenitor cells, loaded with an antigen, 
activated in the presence of granulocyte-macrophage-colony-stimulating factor (GM-
CSF), interleukin (IL)-4 and IL-13. These cells are then re-injected into the 
patient83,84. Whereas, in vivo targeted vaccines refer to direct targeting of natural DC 
subsets at different sites, stimulate and activate DCs in vivo. It has several 
advantages over the ex vivo DC generation. In vivo targeting is less expensive, less 
laborious, easier to standardize, and scale up than the ex vivo DC generation 84.   
 
The first DC-based vaccine approved by the Food and Drug Administration (FDA), 
Sipuleucel-T,85 is a successful example of an ex vivo antigen-loaded DC-based 
vaccine for the treatment of prostate cancer. Patient‘s own peripheral blood 
mononuclear cells (PBMC) including APCs are obtained and in the presence of a 
recombination fusion protein (PA2024) consisting of prostatic acid phosphate (PAP) 
and GM-CSF become activated ex vivo. The cells are then re-injected to the patient. 
Activated APCs are considered to induce an immune response to PAP86,87.  
However, the ex vivo antigen-loaded DC-based vaccine has certain limitation and 
inconveniences. High cost of production and time-consuming preparation are the 
most important which lead to the study of different alternative methods, but with 
similar strategies88. 
 
In vivo activation of DCs and antigen loading is an interesting strategy. It provides a 
physiological environment, targeting of all the DCs subsets present in the 
physiological system and it may be able to overcome all the limitations of ex vivo DC 
Introduction 
22 
 
vaccines88. For in vivo activation, different carrier molecules are used to deliver 
antigens specifically to DCs. The carrier molecules currently used are monoclonal 
antibodies89, nanoparticles90, liposomes91, viruses92, receptor ligands93, synthetic 
long peptides94, and toxins95. 
 
These all carriers have certain limitations such as immunostimulatory effects of 
viruses and toxins96,97, time-consuming preparation,  generation of monoclonal 
antibodies98,99, stability problems with liposomal preparations96, shelf-life of proteins 
or antibodies96, and lack of specificity of nanoparticles and liposomes100.  
 
Aptamers have recently been used as an emerging class of carrier molecules for 
targeted activation of T-cells101. 
 
3.2.3   Macrophages 
Macrophages have a significant role in the innate immune response and, through 
biologically active molecules, in the adaptive immune response. They have a 
significant impact on different human diseases such as infection, allergy, 
inflammation, and cancer102-104.  These cells are located in different organs of the 
body including vital organs such as the liver and brain. They have a specific role in 
maintaining physiological homeostasis in each organ105,106. 
 
These cells have distinct plasticity and the ability to change their phenotype 
according to the microenvironment of the tissue107. They release certain types of 
cytokines to regulate the functioning of other immune cells108. During the 
development and throughout the life span of an individual, macrophages perform 
phagocytic clearance of dying or dead cells and protect the host from different types 
of microbial pathogens109,110.  
 
Over the last few decades, two major phenotypes of macrophages have been 
studied and recognized according to the concept of T helper type 1-T helper type 2 
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(Th1-Th2) polarization111. Mosmann et al.112 have studied that individual clones of 
helper T cells could be distinguished as two classes according to the specific 
cytokines released during antigenic stimulation. Interferon-gamma (IFN-ɤ) and IL-2 
are primarily secreted by Th1 cells, while IL-4,-5,-6,-10 and-13 are secreted by Th2 
cells113. Therefore, the phenotype of macrophages depends primarily on the type of 
cytokines that the macrophages are exposed to (Figure 3.2.2). Cytokines secreted 
by Th1 cells e.g., IFN-ɤ and certain bacterial moieties such as lipopolysaccharide 
(LPS) have the potential to polarize the phenotype of macrophages towards M1 
(classically activated macrophages) (Figure 3.2.2). Whereas, Th2 cell cytokine IL-4 
polarizes macrophages towards M2 (alternatively activated macrophages)111 (Figure 
3.2.2).  In 2014, the spectrum model of macrophages was proposed using nine 
different types of activation stimuli114. The characterization of each phenotype 
identifies a unique macrophage phenotype that is linked to chronic inflammation 
stimuli. The cytokines that polarize macrophages towards TPP macrophage 
phenotype, are tumor necrosis factor, prostaglandin E2, and TLR2-ligand 
(Pam3CSK4)114 (Figure 3.2.2). 
 
Figure 3.2.2: Schematic illustration of the macrophage activation program. Baseline macrophages 
can be differentiated into classically activated macrophages (M1), alternatively activated 
macrophages (M2), and TPP activated macrophages (modified from Xue et al.
114
).  
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3.2.3.1   Classically activated macrophages (M1 or IFN-ɤ) 
Th1 cells secrete IFN-ɤ, which has the potential to drive macrophages polarization 
towards classically activated macrophages (M1 or IFN-ɤ) (Figure 3.2.2). Classically 
activated macrophages are considered to have improved microbicidal, tumoricidal 
effects, and secretion of high pro-inflammatory cytokines properties115,116. These 
cells secrete pro-inflammatory cytokines, reactive oxygen, and nitrogen 
intermediates. They also express MHC II higher/more abundant and are capable of 
presenting antigens. M1 cells have improved the ability to kill invading viruses, 
bacteria or certain type of pathogens117.  LPS, as the main component of Gram-
negative bacteria also polarizes the resting macrophages towards M1 or IFN-ɤ 
phenotype. LPS targets cell surface receptor CD14 on macrophages118. The high 
concentration of LPS can induce CD14 independent polarization119,120. In the 
inflammatory diseases, the production of pro-inflammatory cytokines by classically 
activated macrophages leads to inflammatory response and causes tissue injury121. 
 
3.2.3.2   Alternatively activated macrophages (M2 or IL-4) 
In contrast to classically activated macrophages, alternatively activated 
macrophages secrete anti-inflammatory cytokines to resolve inflammation. They 
produce a particular type of extracellular matrix (ECM) for tissue repair and 
regeneration122,123. Likewise, Th2 polarization, M2 or IL-4 macrophage polarization 
state can be driven by exposure of different cytokine types including, IL-4,-13 and -
10116,123 (Figure 3.2.2).  
 
3.2.3.3   TPP activated macrophages (TNF, PGE2, and TLR2 
Ligand) 
Xue et al.114 used and characterized a new stimulation condition TPP for 
macrophages activation. TPP stimulation condition is closely related to the chronic 
granulomatous inflammation such as granulomatous listeriosis or tuberculosis. TPP 
activated macrophages associated with chronic inflammatory diseases can be driven 
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by exposure to TNF, PGE2, and TLR2 ligand (TPP stimulants) (Figure 3.2.2). In 
2014,  nine different activation programs114, M1 and M2 polarization model were 
extended to the spectrum model of macrophages activation. The M1 and M2 
polarization models were very helpful in the immune studies related only to acute 
infections, allergy, asthma, and obesity124. The observations, which were obtained 
from different studies on macrophages related to chronic inflammation, chronic 
infection and even cancer significantly, illustrate a more diverse spectrum of 
activation depending on the changes in the environment114. 
 
TPP activated macrophages have phenotypic and functional differences from IFN-ɤ 
and IL-4 activated macrophages. Signal transducer and activator of transcription 4 
(STAT4), transcription factor and upregulation of CD14  and CD25 surface markers 
were only identified in the TPP activated macrophages, which makes it distinct from 
the other phenotypes114. At-posttranscriptional level, miRNA 125a-5p is highly 
upregulated and certain miRNAs are downregulated in the TPP macrophages114 
(Figure 3.2.3).  
 
Figure 3.2.3: Overview of miRNA expression level in different macrophage phenotypes 
Five different miRNAs have the same expression level in IFN-ɤ stimulated macrophages. Two 
miRNAs are highly upregulated in IL-4 stimulated macrophages. One miRNA is highly upregulated in 
TPP stimulated macrophages. (miRNA expression level was taken from Xue et al.
114
). 
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3.2.3.4   Macrophages as a therapeutic target 
It has been well accepted that macrophages play an important role in various 
physiological and pathological conditions. They are involved at different levels 
starting from developmental stages to homeostatic functions of the tissues and also 
play a pivotal role in different human diseases125.  During chronic inflammatory 
diseases, macrophages are the key player cells of the body126,127. In the last few 
decades, macrophages have been well studied for their biology, their activation 
programs, and their role in various diseases107,110,114,117,127. But still, it seems difficult 
to target macrophages in a more precise manner.   
 
Schultze128 described in his review (2016), that there is not even a single treatment 
available on the market specifically for macrophages. However, different pre-clinical 
and clinical efforts are currently under investigation to targeting macrophages128-132. 
Previously, the major areas of interest in targeting macrophages include depletion of 
macrophages, reprogramming or re-education of macrophages, and inhibiting the 
recruitment of macrophage125.   
 
“Macrophage depletion” refers to the direct killing of macrophages. They are 
targeted by macrophage-specific cell surface receptors such as colony stimulating 
factor 1 receptor (CSF1R) using anti-CSF1R antibodies or by the use molecules 
such as bisphosphonates and trabectedin. These molecules have the property to 
exert a specific toxic effect against macrophages125,133,134.  This targeting strategy 
may have certain limitations such as inflammatory diseases. If the inflammation is 
limited to a certain part of the body and the macrophages are even depleted from all 
health tissues, it will have a pronounced undesired effect on the physiology and 
homeostatical role of macrophages in all tissues of the body128,135. Macrophage 
depletion is unfavorable in clinical use due to an increased risk of infection when the 
patient is already immune-compromised by side-effects of chemotherapy136.  
 
“Macrophages re-education” or “reprogramming” refers to the properties of 
macrophages to differentiate between different phenotypes according to the micro-
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environmental signals. Therefore, these cells are considered to have a great 
plasticity103,137. This strategy is used in the field of anticancer therapy, to re-educate 
the pro-tumor M2-like macrophages to M1-like macrophages with the antitumor 
properties138,139 (Table 3-2). Song et al.140 have successfully used this strategy with 
bioconjugated manganese dioxide nanoparticles to enhance the chemotherapy 
response with anti-tumor properties140. 
 
“Inhibition of macrophage recruitment” into the tumor cells is another approach to 
targeting the macrophages141 (Table 3-2). The inhibition of chemokine (CCL2) or its 
receptor (CCR2) that regulates the migration of monocytes and macrophages 
significantly affects the overall growth of hepatocellular142 and renal cell 
carcinomas143. Surprisingly, breast cancer metastasis is accelerated following 
cessation of CCL2 inhibition by promoting the angiogenesis144 indicating the 
significance of CCL2 role in regulating metastasis136.  Another chemokine (CXCL12) 
regulates the chemotaxis of macrophages through endothelial barriers to the tumor 
milieu. The stromal cells secrete this chemokine to stimulate the movement of 
cancer cells by upregulation of their CXCR4 receptors145. The pharmacological 
inhibition pathway of CXCL12/CXCR4 provides a promising approach to altering 
macrophage recruitment and combat metastasis145. In the mouse model, treatment 
with CXCR4 antagonist showed a significant reduction in tumor growth as well as in 
combating metastasis of breast cancer146.  
Table 3-2 Different target strategies for tumor-associated macrophages (TAMs) are listed 
(adapted from Panni et al.
141
) 
Target or Drug Mechanism of action 
CCL2-CCR2 axis Prevents monocyte recruitment 
CSF1-CSF1R axis Inhibits/reprograms TAMs 
CXCL12-CXCR4 axis Prevents recruitment of macrophages 
DNA repair mechanisms (trabectedin) Targets TAMs 
Clodronate and zoledronic acid Induces macrophage apoptosis 
Anti-CpG and IL-10 Ab Prevents antitumor to protumor macrophage 
polarization 
CD40 agonist Restores tumor immunity 
Sibilin Suppresses NF-κB and STAT3 
phosphorylation, blocks angiogenesis 
Ab: Antibody; CSF1R: CSF1 receptor; TAM: Tumor-associated macrophage 
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During the last few decades, several studies have described that the activation and 
biological response of macrophages is regulated by miRNAs147. These tiny 
molecular rheostats play a significant role in the innate immune system and 
macrophage biology. They act as a rheostat because of their role as fine-tuning of 
cellular response rather than switching on/off148. The expression levels of different 
miRNAs are significantly altered by the exposure of TLR ligands to THP-1 
monocytes and primary mouse macrophages. These miRNAs have a significant 
effect on macrophage activation biology149,150 and on different phenotypes of 
macrophages as presented in Figure 3.2.3. Therefore, miRNAs might be considered 
to be cell-specific and tissue-specific in different diseases. Thus, targeting strategies 
at the epigenetic and transcriptional level such as miRNAs may have the potential 
for therapeutic options in the future128. 
 
3.3   microRNAs (miRNAs) 
In the early 1990s, approximately 22 and 61 nucleotides long lin-4 transcripts were 
identified in Caenorhabditis elegans (C.elegans)151,152. These sequences were 
complementary to the 3‘ untranslated region (UTR) of lin-14 messenger RNA 
(mRNA). Therefore, Wightman et al.151 proposed that lin-4 regulates the translation 
of lin-14 via an antisense RNA-RNA interaction. Thus, a new non-coding RNA 
regulatory mechanism was discovered, but no single non-coding RNA regulatory 
mechanism was studied in any species until 2000. In 2000, Reinhart et al.153 
reported that lethal-7 (let-7) encodes a non-coding 21-nucleotide long RNA 
sequence, that complementary to the 3‘ UTR regions of the lin-14, lin-28, lin-41, lin-
42, and daf-12 genes. It was an indication that the expressions of these genes were 
controlled by let-7153. Since then, these small non-coding RNAs, now known as 
microRNAs (miRNAs), have been identified in eukaryotes, that are involved in the 
regulation of different developmental and cellular processes154. Interestingly, 60% of 
protein-coding genes in the human genome are regulated by miRNAs155.  These tiny 
RNAs are of significant importance for normal development and play a pivotal role in 
different biological processes156. An abnormal expression level of miRNA is most 
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likely associated with different human diseases157 including diabetes, cardiovascular 
disease, kidney disease, and cancer158.  
 
3.3.1   Biogenesis of miRNAs 
Biogenesis of miRNAs occurs in multiple steps through canonical or non-canonical 
pathways159 (Figure 3.3.1).  Genes for miRNAs are generally transcribed from the 
RNA polymerase II promoters. In the canonical pathway, Drosha, RNase III enzyme 
cleaves the primary miRNA (pri-miRNA) hairpin to the precursor miRNA (pre-
miRNA). While the non-canonical pathway is independent of Drosha and pre-
miRNAs are generated by the mRNA splicing mechanism. Pre-miRNAs generated 
by both pathways are transported to the cytoplasm via a nuclear export protein, 
exportin 5. In the cytoplasm, Dicer, the second RNase III enzyme further processes 
the pre-miRNAs into duplexes159. These miRNA duplexes have a phosphate at the 
5‘ end, a hydroxyl group at the 3‘, and overhangs of 2 nucleotides160. These 
duplexes are then loaded into a functional ribonucleoprotein complex called the 
RNA-inducing silencing complex (RISC) comprising Dicer, trans-activation response 
RNA-binding protein (TRBP), and Argonaute (AGO) proteins. The guide and the 
passenger strands are identified by the TRBP through thermodynamic properties of 
the duplex miRNA159.  Normally, it identifies a strand with a less stable 5‘ end and is 
preferentially loaded into the AGO and is known as the guide strand. The guide 
strand will be unwound from the other strand, known as the passenger strand by 
means of different mechanisms, depending on the extent of their 
complementarity161.  After the strand is selected, the passenger strand leaves the 
activated RISC and the guide strand (mature miRNA). The 5‘ end of the mature 
miRNAs known as seed region (2-8 nucleotides) mediates the binding of mRNA to 
the miRNA-induced silencing complex162.   
One miRNA can regulate hundreds of different targets at the post-transcriptional 
level. There are different regulation mechanisms of miRNAs, such as inhibition of 
translation initiation and mRNA degradation or destabilization163,164.  The 
complementarity between miRNA and mRNA determines the mechanism of 
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regulation. Degradation of mRNA occurs with the 100% complementarity, while 
inhibition of translation occurs when imperfect complementarity with the 
characteristic bulges are formed165. 
 
Figure 3.3.1: Canonical and non-canonical biogenesis pathways of miRNA 
miRNA coding genes are transcribed into pri-miRNAs transcripts by RNA polymerase II. Pri-miRNAs 
have a 5‘ CAP and a poly (A) tail. In the canonical pathway, pri-miRNAs are processed by Drosha-
DGCR8 (DiGeorge syndrome critical region 8), RNA III enzyme complex, to pre-miRNAs. Whereas, in 
the non-canonical pathway pre-miRNAs are generated by mRNA splicing mechanism. Pre-miRNAs of 
the both pathways are exported to the cytoplasm by exportin 5. Dicer, the RNA III enzyme, further 
processes the pre-miRNAs to double stranded miRNA duplexes and loads them into an AGO in the 
RISC and unwound the strands. The guide strand (mature miRNA) is retained in the RISC, while the 
other strand known as the passenger strand is released. The guide strand mediates and recognizes 
the target at 3‘UTRs of target mRNA for inhibition of translation initiation and mRNA degradation or 
destabilization (modified from Li et al.
159
,Stenvang et al.
166
). 
 
3.3.2   miRNAs as a therapeutic target 
The small size and known sequence of miRNAs are unique characteristics for the 
development of drug167. The other characteristic feature of miRNAs is that the 
expression level is altered in different disorders such as metabolic diseases, 
hepatitis C, myocardial infarction, and cancer. Signature patterns of miRNAs are 
conserved in different diseases e.g., some miRNAs are upregulated and some are 
downregulated in a particular disease168. The fine-tuning of miRNAs through 
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antisense oligonucleotides (ASO) may have a long-lasting therapeutic effect. The 
upregulated miRNA can be inhibited by antagomir166 and the downregulated 
miRNAs expression can be restored through double-stranded miRNA mimics169. 
Recently, the targeting of miRNAs presents a potent tool for therapeutic intervention 
in different diseases167.  
 
3.3.3   Strategies for miRNAs manipulation  
There are two main strategies for the manipulation of miRNAs. Depending on the 
expression level of miRNAs, either the targeted miRNAs expression level needs to 
be inhibited or restored by re-introducing miRNAs167. 
   
 Restoration or introduction of miRNAs: During the progression of different diseases 
including cancer, the miRNA expression level was altered or downregulated. The 
expression level could be restored by transfecting exogenous double-stranded 
miRNAs or using the vector to express the desired miRNA167. Restoration of miRNA-
29b in glioblastoma cancer cells has the potential to inhibit the expression of 
different genes, resulting in anti-cancer effects170. Likewise, the delivery of 
exogenous miRNA-34a with NOV340 liposome resulted in the tumor reduction and 
prolonged survival in the animal models171. The Phase I clinical trial to restore the 
function of miRNA-34a also showed safety and anti-tumor activity in patients with 
advanced solid tumors172. 
   
Antagomir for inhibition of miRNAs: miRNA antagonists (antimiRs) or an antagomir 
are oligonucleotides having a complementary sequence of endogenous 
miRNAs167. These chemically modified ASO are widely used in the miRNA loss-of-
function studies173. Chemical modifications are required to increase binding affinity, 
enhanced nuclease resistance, and in vivo delivery173. These modifications are 
classified as first generation, second generation, and third generation 
modifications. Modifications of the first generation are used to enhance nuclease 
resistance by the introduction of phosphorothioate (PS) bond in the phosphate 
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backbone of the ASO (Figure 3.3.2). These modifications also include modulation 
of the phosphodiester backbone, the sugar moiety, and heterocyclic nucleobase to 
improve affinity and specificity.  The first antisense drug approved by the FDA is 
Vitravene, a first generation PS-ASO, for the treatment of AIDS-related 
cytomegalovirus (CMV) retinitis174. Unfortunately, Vitravene is discontinued in 
Europe and the United States due to the development of high-activity anti-retroviral 
therapy (HAART)175. Most drugs based on first generation modifications in Phase I 
clinical trials are PS modified. However, their binding profile to the target RNA 
sequence and specificity are less satisfactory with low cellular uptake.  The 
limitations associated with the first generation oligonucleotides are addressed by 
second generation modification176. 
 
In the second generation modification, the sugar moiety of nucleobase is modified 
to improve the binding affinity to the target RNA. The most promising modifications 
include 2‘-O-Methyl (2‘-O-Me), 2‘-O-methoxyethyl (2‘-O-MOE), and Locked Nucleic 
Acids (LNAs)176 (Figure 3.3.2).  2‘- substitution on the furanose ring of the RNA is 
one of the structural differences between DNA and RNA. Therefore, the ASO 
binding affinity to the target RNA may be enhanced by mimicking RNA structures 
with the 2‘- modified nucleosides.  The introduction of the 2‘-O, 4‘-methylene bridge 
in the sugar-phosphate backbone of the furanose ring locked in the conformation of 
the RNA mimicking N-type (C3‘-endo) in the LNA modified ASO. The other 
modifications such as substitution of electronegative fluorine and oxygen also affect 
the furanose ring in the C3‘-endo conformation166. Meister et al.177 demonstrated for 
the first time that 2‘-O-Me modified oligonucleotides inhibit the sequence-specific 
miRNA in the cultured mammalian cells for the loss-of-function studies. 
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Figure 3.3.2: Chemical modifications of antagomir oligonucleotides 
A-D) The sugar backbone of antagomir oligonucleotides is modified to increase the stability and 
affinity of oligonucleotides. E) The phosphate backbone of the oligonucleotides is modified to 
enhance nuclease resistance by the introduction of phosphorothioate (PS) bond (modified from 
Stenvang et al.
173
). 
 
3.3.4   Mechanism of action of antagomir 
Several steps may be targeted during the biogenesis of mature miRNAs for the 
inhibition or loss-of-function studies. Targets may include pri-miRNA transcripts, 
intermediate pre-miRNA stem-loop structure or mature miRNA. The most 
promising target is mature miRNA because two other targets have certain 
limitations such as the design of antagomir due to thermodynamic challenges and 
the different complications of in vitro studies (e.g., the presence of mature miRNAs 
in the cytoplasm negatively interferes with the detection of inhibition)178. 
 
The standard antagomir used to inhibit mature miRNA must be perfectly 
complementary to the full length of the targeted miRNA179. The ideal antagomir has 
the property to sterically block the target miRNA from binding to the mRNA. The 
antagomir forms a duplex with a miRNA guide strand and leads to loss-of-function. 
The potency of an antagomir is increased by chemical modifications that enhance 
duplex stability and nuclease resistance.  The binding affinity of the duplex needs 
to be significantly higher than that of the miRNA guide and the passenger strand 
Introduction 
34 
 
duplex in order to prevent the unwinding by helicase activity179,180. The antagomir 
needs to bind to the target miRNA either in a single-stranded form or when it is 
bound to an AGO in the RISC179. ―Seed region‖ of miRNA (2-8 nucleotides) at the 
5‘ UTR is well organised and exposed in the AGO to support the binding to the 
complementary site to the target mRNA180,181. Tiny modified LNA, complementary 
to the seed region of miRNA, is also capable to inhibiting miRNA and family of 
miRNA sharing the same seed region181. The mechanism of miRNA inhibition by 
the antagomir oligonucleotides is shown in Figure 3.3.3.  
 
Figure 3.3.3: Mechanism of action of antagomir oligonucleotides 
Left: Endogenous miRNA binds to the target mRNA leading to translation inhibition. Right: 
Chemically modified antagomir binds to mature miRNA in competition with the 3‘UTR of the cellular 
target mRNA leading to functional inhibition of the miRNA (modified from Stenvang et al.
173
). 
 
3.4   Aims of the thesis 
The aim of this study was to investigate the potential role of macrophage-binding 
aptamer as a delivery tool for delivering antagomir 125a-5p in human baseline 
macrophages. In particular, we were interested to reprogramming TPP 
macrophages to other macrophage phenotypes.  
 
The mature miRNAs are from the family of small non-coding RNAs that have a 
regulatory effect on the expression of various genes. Endogenous miRNAs play a 
significant role in the fine-tuning of cellular responses. Over the past decades, 
miRNAs have been known to be an important regulator of macrophage activation 
and biological response. miRNA 125a-5p is highly upregulated in chronic 
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inflammatory macrophages (TPP). We hypothesized that inhibition of miRNA 125a-
5p could have an impact on the overall polarization state of TPP macrophages. The 
use of high affinity and complementary nucleic acid (antagomir 125a-5p) can inhibit 
endogenous miRNA 125a-5p. However, antagomirs have limited therapeutic efficacy 
due to poor cellular uptake. As a result, various carrier molecules are in use to 
facilitate transport across the cellular membrane.  
 
In the current study, ssDNA aptamer (DC 12) was used as a carrier molecule for the 
delivery of antagomir 125a-5p to human baseline macrophages. DC 12 aptamer was 
covalently linked to the antagomir 125a-5p and thus constructs a chimera known as 
aptamiR. DC 12 aptamer was screened from the NGS data of BM-DCs cell-SELEX. 
Potential targeted delivery vehicles have to meet several criteria. They need to bind 
to their target cells with high affinity and specificity and internalize for the efficient 
delivery of cargo molecules. Flow cytometry binding assay and confocal microscopy 
can be used to analyze the binding and internalization of the DC 12 aptamer. The 
aptamiR 125a-5p chimera interaction with the cells and inhibition of endogenous 
miRNA 125a-5p was studied. In addition, the carrier properties of DC 12 aptamer 
were further validated by the aptamer guided delivery of OT-I peptide to DCs for 
targeted activation of CD8 T cells. 
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4   Results 
The potential of the selected ssDNA aptamer, used as a delivery vehicle in the 
macrophages and DCs, is described in this chapter. Practically the study was 
conducted in five phases and so the chapter is also divided into five sections.  
The first two Sections 4.1 and 4.2 describe the characterization of ssDNA aptamers 
targeting different monocytes/macrophages cell lines, BM-DCs, primary, and 
differentiated human macrophages. The third Section 4.3 describes EGFP-4X125a-
5p reporter gene construction and investigations using miRNA 125a-5p mimic. The 
stable cell line was constructed with the reporter gene. The interaction studies were 
conducted, including inhibition of miRNA 125a-5p in the stable cell line using the 
antagomir 125a-5p and the binding studies.  
Whereas, the fourth Section 4.4 deals with the construction of the aptamer-
antagomir 125a-5p conjugates (aptamiR 125a-5p) and the pharmacological effect of 
aptamiR on the inhibition of miRNA 125a-5p. 
The last Section 4.5 concludes with the construction of aptamer-peptide conjugates 
and the targeted delivery of antigen for CD8 T cell activation. 
 
4.1   Analysis of binding capacity (affinity) and specificity 
of aptamers sequences to macrophages and DCs 
Macrophages are immune cells that share a monocyte-macrophage DC progenitor 
as a common precursor to monocytes and DCs182. Macrophages and DCs are 
professional APCs and might have common cell surface receptors that facilitate this 
process. In general, macrophage targeting aptamers can be selected through the 
cell-SELEX approach183.  BM-DCs cell-SELEX was previously performed in our 
lab101 and in the preliminary analysis, the aptamer sequences selected from BM-
DCs cell-SELEX showed an affinity towards the macrophages101. There might have 
been some sequences that recognize macrophages as they shared the same 
progenitor and functions as DCs. The NGS data of BM-DCs cell-SELEX showed that 
selection cycle 1 contains 100% unique sequences and that the percentage of 
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unique sequences decreased to 50% in the 10th selection cycle.  The complexity of 
the selection cycle gradually decreased starting from the 3rd selection cycle and 
certain DNA sequences became more abundant101.      
The NGS data of the BM-DCs cell-SELEX was used and the most abundant 
sequences (Table 4-1) from the 10th selection cycle were tested with macrophage 
cell lines. To identify the most promising sequence to be used as a delivery vehicle.  
Table 4-1: The most abundant sequences identified from the NGS data of BM-DCs cell-
SELEX
101
 
DC Random region 5’-3’ 
4 GGGGAGGTGGGTGGGTTGGCCTTCACGTTATCTTTTGGTGGTT 
6 CCAGGGGAGGATGGGAGGGTTTTTTTCGGATTCTTGTCGTGCT 
7 CGTGGTATGTGGTGGGTGGTGGGGTGGTAGTTGGGTGGACGGT 
8 CAGGGGAGGTGGGTGATTGGGTTGTTTTTCGCGGACGTGAGGT 
10 CGAGTTTCTGAGGGTGGGTGGGTGGTTATTAGTCGAGGTTGCA 
12 CCAGGGTGGGATGGGTATTTTGAGGTGGAGGTGGGGGTTGGTT 
13 GGGTGTTGTGGGGTGGGGCGGTGGGTGTGAGTGTCGGCAGCTG 
14 TGTGGTTCGGTAGGTCGGGGAGGGTGGTGGGTTATGCGGCGGG 
15 CACAGGGGAGGTCGGGCGGGTTGTCTGCTTTCTTGGGTCGGTT 
20 CGTACTTTCACACGGGGAGGTGGGTTGGGTTCTGATTAGGGTT 
21 CTGGGTCGGGGGTATTGTTTGCGATATGGGGGGTTTTGGGGTG 
 
4.1.1   Binding of the ssDNA sequences to the J774A.1 
cells (mouse macrophages) 
The Cherenkov assay was performed to investigate the binding capacity (affinity) of 
the sequences (Table 4-1) towards macrophages (Figure 4.1.1). Herein, the 
J774A.1 cell line (mouse macrophages) was used as a target. Since the sequences 
were selected from the BM-DCs cell-SELEX, they could recognize mouse 
macrophages because both express many common molecules184. 11 the most 
abundant sequences (Table 4.1.1) were tested in the Cherenkov assay from the 
NGS data.32P-DNA was incubated with J774A.1 cells in the DMEM medium 
supplemented with 10% FCS at 37°C for 10 minutes. The percentage of bound 32P-
DNA has been calculated. All the sequences have the potential to bind to J774A.1 
cells compared to control (Ctrl 2). Ctrl 2 was used as a non-specific control DNA 
sequence. This sequence was also used as a control in the characterization of BM-
DCs selected aptamers. Ctrl 2 was a scrambled sequence of the CTL#5 aptamer 
from the protein-SELEX targeting the recombinant protein Fc-CTL101. The 
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percentage of bound DNA greater than Ctrl 2 indicates binding towards 
macrophages (Figure 4.1.1). The sequences (1 pmol of 32P-labeled DNA) showed 
6-8% binding to the cells in Cherenkov assay. 6-8% 32P-DNA bound with the cells is 
considered high because the number of aptamer molecules is greater than the total 
number of cells used for Cherenkov assay. For instance, 1 pmol contains 6.022x1011 
molecules of the aptamer in Cherenkov assay (1 mole is equal to 6.022x1023 
molecules, Avogadro's number). 6-8% of 1 pmol contains approximately have 
3.6x1010 - 4.8x1010 molecules of the aptamer bound to the cells (3.6x1010 - 4.8x1010 
molecules > 0.5x105 cells). Thus, 6-8% of the bound aptamer is considered to be 
high. 
 
Figure 4.1.1: Binding of the ssDNA sequences to J774A.1 cells (mouse macrophages) 
The most abundant NGS sequences from the cell-SELEX of BM-DCs show binding towards mouse 
macrophages (J774A.1).1 pmol 
32
P-labeled DNA was incubated with 0.5×10
5
 J774A.1 cells. Liquid 
scintillation was used to determine the percentage of the bound DNA sequences to the cells. (n=3, 
mean ± SD). 
 
In order to further confirm the Cherenkov assay, a flow cytometry assay was used to 
assess the binding to macrophages. Three sequences (DC 7, DC 10, and DC 12) 
were selected from chenrenkov assay, which had a higher mean percentage of cells 
bound, to be tested in the flow cytometry assay. 5‘-ATTO 647N- labeled Ctrl 2, DC 7, 
DC 10, and DC 12 were incubated with 4x105 cells in the DMEM medium 
supplemented with 10% FCS at 37°C for 10 minutes.  
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Table 4-2: Percentage (%) J774A.1 cells bound by ATTO 647N-labeled aptamers and relative 
mean fluorescence intensity (MFI) in flow cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2* 8.60±4.8 1.01±0.16 
DC 7 63.6±2.8 3.35±0.76 
DC 10 62.8±4.5 3.19±0.67 
DC 12 81.3±2.9 3.97±0.59 
D#23 81.2±2.6 4.18±0.75 
 * control  
 
Subsequently, the percentage of cells bound by DNA and the mean fluorescence 
intensity (MFI) was detected by flow cytometry (Table 4-2 and Figure 4.1.2). D#23 
aptamer was also included in the flow cytometry binding assay as a positive 
control101 (Table 4-2 and Figure 4.1.2). D#23 showed the binding ability to BM-DCs 
as well and it is a two-point mutant of D#7 aptamer. D#7 was a well-characterized 
aptamer targeting BM-DCs and was used in the aptamer-targeted delivery of antigen 
to DCs for T cells activation101.   
 
Figure 4.1.2: ATTO 647N-labeled aptamers binds to J774A.1 cells in flow cytometry binding 
assay 
 4×10
5
 J774A.1 cells were incubated with 250 nM of 5‘-ATTO 647N-labeled aptamers at 37°C for 10 
minutes.A) The percentage of cells bound by aptamers and B) relative MFI (aptamer/control) were 
measured by flow cytometry.(D#23 aptamer was used as a positive control
101
) (n=3, mean ± SD). 
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4.1.2   Binding of aptamers to THP-1 cells (human 
monocytic cell line) 
The binding potential of the ssDNA sequences was described in the J774A.1 cell 
binding assay (Figure 4.1.1 and Figure 4.1.2), resulting in the identification of DC 7, 
DC 10, and DC 12 aptamers, which showed binding to the mouse macrophages. 
THP-1 cells were used as target cells to test the binding ability to the human cell line 
or human origin. Human monocytes have properties to differentiate either as 
monocyte-derived macrophages or as monocyte-derived DCs185,186. Therefore, 
binding experiments with THP-1 cells are worthwhile. These cells are taken from 
human sources and are capable of being differentiated into human macrophages 
and DCs, like cells. 
Table 4-3: % THP-1 cells bound by ATTO 647N-labeled aptamers and relative MFI in flow 
cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2* 3.70±1.13 1.0±0.19 
D#23 21.7±5.63 2.3±0.58 
DC 7 17.8±4.17 2.4±0.63 
DC 10 9.70±3.16 1.9±0.42 
DC 12 52.4±5.39 3.5±0.64 
 *control 
 
A flow cytometry assay (Table 4-3 and Figure 4.1.3) was used to analyze the 
binding of aptamers to THP-1 cells.  5‘-ATTO 647N- labeled aptamers Ctrl 2, DC 7, 
DC 10, and DC 12 were incubated with 4x105 cells in the RPMI 1640 medium 
supplemented with 10% FCS at 37°C for 10 minutes. The percentage of cells bound 
by DNA and MFI was detected by the flow cytometry. DC 12 showed 52.4±5.39% 
cells bound while the other aptamers (DC 7, DC 10, and D#23) showed a lower 
percentage of bound cells (Table 4-3). THP-1 cells are from the human source and 
are not well developed/differentiated into macrophages or DCs, which might be the 
reason for the decrease in the binding of the aptamers. The main aim of this study 
was to use macrophage-binding aptamer to delivery antagomir 125a-5p into human 
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baseline macrophages. Therefore, aptamers with a high percentage binding to 
human cells (THP-1) were chosen for further analysis. 
Thus, D#23 and DC 12 were further analyzed because they have a higher potential 
to recognize human monocytic cells compared to the other two aptamers (Figure 
4.1.3).  
 
Figure 4.1.3: ATTO 647N-labeled aptamers binds to THP-1 cells in flow cytometry binding 
assay 
4×10
5
 THP-1 cells were incubated with 250 nM of 5‘-ATTO 647N-labeled aptamers at 37°C for 10 
minutes. A) The percentage cells bound by aptamers and B) relative MFI (aptamer/control) were 
measured by flow cytometry.D#23 aptamer was used as a positive control
101
 (n=4, mean ± SD). 
 
The concentration-dependent binding of DC 12 and D#23 to THP-1 cells, was 
analyzed using a flow cytometry binding assay. Ctrl 2 (scrambled control), D#23, 
and DC 12 labeled with 5‘-ATTO 647N were incubated with THP-1 cells with the 
increasing concentration (10 nM - 5000 nM). The cells were incubated with the 
aptamers at 37°C for 10 minutes. The mean fluorescence intensity (MFI) was 
measured by flow cytometry (Table 4-4 and Figure 4.1.4).  
Table 4-4: MFI of THP-1 cells bound by ATTO 647N-labeled aptamers in flow cytometry binding 
assay 
Concentration (nM) 
MFI 
Ctrl 2 D#23 DC 12 
10 
25 
50 
100 
250 
500 
750 
1000 
2500 
5000 
1.60±0.24 
1.67±0.27 
2.07±0.39 
2.15±0.48 
2.79±0.85 
3.91±0.91 
4.06±1.05 
5.09±1.39 
9.75±1.86 
17.10±1.61 
2.50±0.64 
2.93±1.14 
3.39±1.55 
5.99±2.90 
8.18±5.46 
9.43±4.48 
12.49±5.97 
11.95±4.76 
21.25±6.20 
33.48±7.84 
2.63±0.90 
3.49±1.44 
4.12±1.71 
6.72±3.27 
9.68±5.46 
14.15±6.24 
19.23±7.51 
21.38±5.75 
32.80±8.29 
44.23±8.73 
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DC 12 was shown to have higher MFI compared to D#23. MFI of the Ctrl 2 was also 
increased at the last two concentrations but it was still less than aptamers. It might 
be due to the unspecific uptake of the high concentrated DNA in the surrounding 
fluid through endocytosis. The concentration-dependent binding curve is not 
saturated even at the high concentration. It may be due to the continuous 
internalization of aptamers. As shown in Figure 4.1.4, there is an increase in the 
MFI with increasing the concentration. All aptamers showed the concentration-
dependent binding to the human monocytic cell line (THP-1).  
 
Figure 4.1.4: ATTO 647N-labeled aptamers bind in a concentration dependent manner to THP-1 
cells 
4×10
5
 THP 1 cells were incubated with increasing concentration (10 nM – 5000 nM) of 5‘ ATTO 
647N-labeled aptamers for 10 minutes at 37°C.The mean fluorescence intensity of 5‘ ATTO 647N-
labeled aptamers were measured by the flow cytometry (n=2, mean ± SD). 
 
Taking into account the binding capability of DC 12 aptamer towards mouse 
macrophages and human monocytes, DC 12 aptamer was selected for further 
characterization. 
 
4.1.3   Binding of aptamers to BM-DCs 
DC 12 aptamer is one of the most abundant sequences from the NGS data of BM-
DCs cell-SELEX. In Section 4.1.1 and Section 4.1.2, DC 12 aptamer was identified 
for binding to macrophages. As DC 12 aptamer was intended to be used as a 
delivery vehicle for the targeted activation of T cells, the binding to BM-DCs needed 
to be determined. 
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Table 4-5: % BM-DCs bound by ATTO 647N-labeled aptamers and relative MFI in flow 
cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2* 9.82±2.14 1.00±0.03 
DC 12 72.1±9.85 3.91±1.15 
D#23 75.5±9.72 4.00±0.53 
 *control 
 
For that purpose, the binding of the aptamers to BM-DCs was analyzed by the flow 
cytometry assay. 5‘-ATTO 647N- labeled aptamers Ctrl 2, DC 12, and D#23 were 
incubated with 4x105 cells in the DC medium supplemented with 10% FCS for 10 
minutes at 37°C. The percentage of cells bound by DNA and MFI was detected by 
the flow cytometry (Table 4-5 and Figure 4.1.5). DC 12 and D#23 aptamer showed 
the potential to bind to BM-DCs. 
 
Figure 4.1.5: ATTO 647N-labeled aptamers binds to BM-DCs in flow cytometry binding assay 
4×10
5
 BM-DCs were incubated with 250 nM of 5‘-ATTO 647N-labeled aptamers for 10 minutes at 
37°C. A) The percentage cells bound by aptamers B) relative MFI (aptamer/control) were measured 
by flow cytometry.D#23 aptamer was used as a positive control
101
 (n=2, mean ± SD). 
 
4.2   Characterization of DC 12 aptamer 
4.2.1   Immunogenicity of aptamers 
In order to investigate the immunogenicity of DC 12 and D#23, TNF-α secretion was 
measured by homogeneous time-resolved fluorescence (HTRF) assay. It was done 
in collaboration with Prof. Eicke Latz. Immune cells have the ability to detect 
exogenous or host nucleic acids via pattern recognition receptors (PRRs) e.g., Toll-
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like receptors (TLRs). These receptors are expressed both on the cell surface and 
also in the endosomal compartments. They can detect nucleic acid ligands and 
activates the signal cascade that results in the secretion of proinflammatory 
cytokines including TNF-α secretion187,188. 
The basic principle of HTRF assay is established on fluorescence resonance energy 
transfer (FRET). Anti-TNF-α antibodies were bound with either a FRET donor or an 
acceptor molecules. These molecules were able to alter the fluorescence emission 
spectrum in close proximity to antibodies. This change is relative to the 
concentration of TNF-α in the sample.  
 
Figure 4.2.1: DC 12 and D#23 do not induce TNF-α secretion in macrophages 
Immortalized murine embryonic stem cells derived from macrophages were treated with increasing 
concentrations of positive controls (LPS and CpG ODN motif), DC 12 and D#23 for 24 hours. TNF-α 
secretion in the supernatants were determined by HTRF assay (n=5 , mean ± SD). The assays were 
performed as blinded analysis by James Stunden, member of Prof. Latz group, University Hospitals 
Bonn. 
 
The TLR activation investigation was performed using immortalized murine 
embryonic stem cell-derived macrophages. LPS and CpG ODNs, known as TNF-α 
inducers, were used as positive controls. In general, LPS is considered a key 
component of the superficial membrane of Gram-negative bacteria.The innate 
immune response can be initiated even at a minute amount by TLR189. Whereas, 
CpG ODNs are synthetic oligodeoxynucleotides consisting of unmethylated CpG 
motifs (cytosine-phosphodiester or phosphorothioate-guanosine). These 
unmethylated motifs elicit cells have TLR 9 and initiate an innate immune response 
with the production of proinflammatory cytokines and Th1190. Both positive controls 
trigger the cells and activate TNF-α secretion at concentrations in the nanomolar 
range (Figure 4.2.1). The aptamers DC 12 and D#23 showed low TLR activation 
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even at the highest concentration (Figure 4.2.1). As a result, DC 12 and D#23 
aptamers have been shown to be less immunogenic and could be used in 
therapeutic and diagnostic applications for immune cells. 
 
4.2.2   Truncation of DC 12 aptamer and G-quadruplex 
structure prediction 
DC 12 is 80 nucleotides. The structure of DC 12 was predicted using mfold 
prediction software191. The structure consists of a loop, a stem, and a tail on both 
ends (Figure 4.2.2A). The DC 12 loop and stem might have some impact on the 
binding behavior of the aptamer. The primer binding site from the 3‘ (15 nucleotides) 
and 5‘ (12 nucleotides) ends was cut and DC 12 was truncated to 53 nucleotides. 
The truncated structure on the mfold was predicted (Figure 4.2.2B). The parental 
loop and stem of the DC 12 aptamer were not affected. 
 
Figure 4.2.2: Truncation of DC 12 
Mfold online prediction software has been used to predict the secondary structure of DC 12 aptamer 
(A). The primer binding site from 3‘ (15 nt) and 5‘ (12 nt) end was cut (B) to generate DC 12.53.  
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The aptamer DC 12 is a G-rich sequence and the G-rich sequences have properties 
for the formation of the G-quadruplex structure. G-quadruplex is one of the most 
important structures observed in nucleic acids particularly by the ssDNA. The 
understanding of the G-quadruplex is important for diagnostic and therapeutic 
applications but also for the structural activity and natural biochemistry of nucleic 
acids192. 
In order to determine whether DC 12 and DC 12.53 could have a G-quadruplex 
structure, circular dichroism (CD) was performed. Aptamer C10.36 was used as a 
positive control. It is folded into a parallel G-quadruplex in DPBS193. 10 µM 
concentration of the aptamers DC 12 and DC 12.53 were prepared in DPBS and in 
ddH2O. JASCO J-810 CD spectrometer was used to measure the CD of the 
aptamers over a wide range of wavelengths. The aptamers (DC 12 and DC 12.53) 
fold in parallel manner in the DPBS when compared to the positive control C10.36 
(Figure 4.2.3). The positive peak ranging from 260-265 nm and the negative peak 
ranging from 240-245 nm indicates parallel G-quadruplex structure in the CD 
spectroscopy. 
 
Figure 4.2.3: CD-spectroscopy of the aptamers for the prediction of G-quadruplex structure 
10 µM concentration was used to measure the CD spectra of aptamers. C10.36 (black line) was used 
as a positive control. DC 12 (blue dotted line), DC 12.53 (light grey dotted line), DC 12.53sc1 (red 
dotted line) in DPBS. 
 
 In ddH2O, both aptamers lose their G-quadruplex structure due to the absence of 
monovalent cations (Figure 4.2.4). Potassium and sodium ions play a central role in 
the formation and stability of the G-quadruplex194, present in DPBS but not in 
ddH2O. 
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Figure 4.2.4: CD-spectroscopy of the aptamers in the absence of ions 
10 µM concentration was used to measure the CD spectra of aptamers in the absence of ions. 
C10.36 (black line) was used as a positive control. C10.36 (ddH20) (black dotted line), DC 12 (ddH20) 
(blue dotted line), DC 12.53(ddH20) (red dotted line) in ddH20. 
 
The binding affinity of DC12.53 aptamer was again tested on both model cell lines 
J774A.1 (Table 4-6 and Figure 4.2.5) and THP-1 (Table 4-7 and Figure 4.2.6).  
Table 4-6: % J774A.1 cells bound by ATTO 647N-labeled aptamers and relative MFI in flow 
cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2* 12.3±0.3 1.00±0.01 
DC 12 86.4±6.9 4.09±0.8 
DC 12.53 88.1±7.3 4.07±0.5 
DC 12.53sc1** 15.5±2.0 1.00±0.03 
DC 12.53sc2 14.9±2.0 0.95±0.08 
 *control for DC 12 
 ** control for DC 12.53 and DC 12.53sc2 
 
DC 12.53sc1 was a scrambled sequence of DC 12.53 aptamer with the same 
number of nucleotides and the nucleotide content. DC 12.53sc2 was also a 
scrambled sequence of DC 12.53 with the same number of nucleotides but with 
different nucleotides (G was replaced by either A or T, to decrease the stability of the 
secondary structure). The flow cytometry binding assay with J774A.1 cells showed 
that ATTO 647N labeled DC 12.53 had the same percentage of cells bound and 
relative MFI as DC 12 (Table 4-6 and Figure 4.2.5).  
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Figure 4.2.5: Truncated DC 12 binds to J774A.1 cells 
4×10
5
 J774A.1 cells were incubated with ATTO 647N-labeled aptamers. A) The percentage cells 
bound by ATTO 647N labeled aptamers and B) relative MFI (aptamer/control) were measured by flow 
cytometry (n=3, mean ± SD). 
 
Interestingly, DC 12.53 showed almost 40% increase in the binding and relative MFI 
with THP-1 cells compared to DC 12 (Table 4-7 and Figure 4.2.6). DC 12.53sc1 
was used as a control sequence for further experiments because it has the same 
nucleotide number and nucleotide content. 
Table 4-7: % THP-1 cells bound by ATTO 647N-labeled aptamers and relative MFI in flow 
cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2* 3.15±0.6 1.00±0.03 
DC 12 57.9±8.3 4.15±0.52 
DC 12.53 91.1±3.5 6.61±0.6 
DC 12.53sc1** 3.60±1.1 1.01±0.12 
DC 12.53sc2 3.19±0.7 0.87±0.13 
 *control for DC 12 
 **control for DC 12.53 and DC 12.53sc2 
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Figure 4.2.6: Truncated DC 12 binds to THP-1 cells 
4×10
5
 THP 1 cells were incubated with ATTO 647N-labeled aptamers. A) The percentage cells bound 
by ATTO 647N labeled aptamers B) relative MFI (aptamer/control) were measured by flow cytometry 
(n=3, mean ± SD). 
 
4.2.3   Binding of the 3’ labeled DC 12 and DC 12.53 
In the previous experiments, 5‘ ATTO 647N-labeled DC 12 and DC 12.53 were 
characterized for their binding ability to THP-1 and J774A.1 cells. The labeling 
strategy could affect the folding and binding behavior of the aptamer. In this study, 3‘ 
end of the aptamer was also used to conjugate antagomir 125a-5p for the inhibition 
of miRNA 125a-5p. It is therefore worth investigating the folding behavior of the 
aptamer after changing the labeling strategy. In order to investigate the impact of the 
labeling strategy, ATT0 647N-label was introduced into the 3‘ end instead of the 
5‘end of DC 12 and DC 12.53. 
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Table 4-8: % J774A.1 cells bound by ATTO 647N-labeled aptamers and relative MFI in flow 
cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2_5‘* 8.87±1.87 1.00±0.09 
DC 12_5‘ 78.7±8.21 3.01±0.64 
Ctrl 2_3‘** 14.4 ±2.42 1.00±0.08 
DC 12_3‘ 84.1±2.58 2.54±0.24 
5‘_DC 12.53sc1
#
 12.5±0.38 1.00±0.01 
5‘_DC 12.53 89.0 ±6.03 4.53±0.24 
3‘_DC 12.53sc1
##
 14.4±1.68 1.00±0.02 
3‘_DC 12.53 68.5±2.98 2.62±0.34 
DC 12_5‘ and Ctrl 2_5‘ was labeled at 5‘ end and DC 12_3‘ and Ctrl 
2_3‘ was labeled at 3‘ end with ATTO 647N. 5‘_DC 12.53 and 5‘_DC 
12.53sc1 was labeled at 5‘ end and 3‘_DC 12.53 and 3‘_DC 
12.53sc1 was labeled at 3‘ end with ATTO 647N.  
*control for DC 12_5‘ 
**control for DC 12_3‘ 
#
control for DC 12.53_5‘ 
##
control for DC 12.53_3‘
 
 
The binding ability of 3‘ labeled DC 12 and DC 12.53 were compared to 5‘ labeled 
DC 12 and DC 12.53. The aptamers were incubated with 4x105 cells (THP-1 and 
J774A.1) in the cell culture medium supplemented with 10% FCS at 37°C for 10 
minutes. The percentage of cells bound by DNA and MFI were detected by the flow 
cytometry. 3‘ ATTO 647N-labeling did not influence the binding behavior of DC 12 
aptamer compared to 5‘ ATTO 647N-labeled DC 12 with J774A.1 cells (Table 4-8 
and Figure 4.2.7A,B). However, 3‘ ATTO 647N-labeled DC 12.53 showed 
approximately 20% less binding compared to 5‘ ATTO 647N-labeled DC 12.53 
(Table 4-8 and Figure 4.2.7C,D). This reduction in the percentage of bound cells by 
DNA could be due to the stability or alteration of the structure of 3‘ ATTO 647N-
labeled DC 12.53. 
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Figure 4.2.7: Comparison of binding of 3’ and 5’ ATTO 647N-labeled aptamers to J774A.1  
A+B) DC 12 and Ctrl 2 was labeled at 5‘ end (DC 12_5‘ and Ctrl 2_5‘) and 3‘ end (DC 12_3‘ and Ctrl 
2_3‘) with ATTO 647N. C+D) DC 12.53 and DC 12.53sc1 was labeled at 5‘ end (5‘_DC 12.53 and 
5‘_DC 12.53sc1) and 3‘ end (3‘_DC 12.53 and 3‘_DC 12.53sc1) with ATTO 647N.4×10
5
 J774A.1 
cells were incubated with 250 nM of 3‘and 5‘-ATTO 647N-labeled aptamers at 37°C for 10 minutes. A 
and C) The percentage of cells bound by aptamers and B and D) relative MFI (aptamer/control) were 
measured by flow cytometry (n=3, mean ± SD). 
 
 3‘ ATTO 647N-labeled DC12 showed 10-15% increase in the binding to THP-1 cells 
compared to 5‘ ATTO 647N-labeled (Table 4-9 and Figure 4.2.8A,B). This increase 
in the percentage of cell bound by DNA could be due to the stabilization of the 
structure or an increase in the binding affinity towards the target. However, 3‘ ATTO 
647N-labeled DC 12.53 did not influence the binding behavior of THP-1 cells 
compared to 5‘ ATTO 647N- labeled DC 12.53 (Table 4-9 and Figure 4.2.8C,D). Ctrl 
2 and DC 12.53sc1 were used as control sequences, which showed no binding 
behavior (Figure 4.2.7 and Figure 4.2.8).  
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Table 4-9: % THP-1 cells bound by ATTO 647N-labeled aptamers and relative MFI in flow 
cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2_5‘* 3.74±0.7 1.00±0.1 
DC 12_5‘ 59.9±7.7 4.01±0.5 
Ctrl 2_3‘** 4.32 ±1.3 1.00±0.09 
DC 12_3‘ 73.3±4.0 3.47±0.3 
DC 12.53sc1_5‘
#
 5.29±0.3 1.00±0.1 
DC 12.53_5‘ 94.7±2.7 6.04±1.1 
DC 12.53sc1_3‘
##
 5.93±0.7 1.00±0.01 
DC 12.53_3‘ 81.8±9.1 3.30±0.4 
DC 12_5‘ and Ctrl 2_5‘ was labeled at 5‘ end and DC 12_3‘ and Ctrl 
2_3‘ was labeled at 3‘ end with ATTO 647N. 5‘_DC 12.53 and 5‘_DC 
12.53sc1 was labeled at 5‘ end and 3‘_DC 12.53 and 3‘_DC 
12.53sc1 was labeled at 3‘ end with ATTO 647N.  
*control for DC 12_5‘ 
**control for DC 12_3‘ 
#
control for DC 12.53_5‘ 
##
control for DC 12.53_3‘
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Figure 4.2.8: Comparison of binding of 3’ and 5’ ATTO 647N-labeled aptamers toTHP-1 
A+B) DC 12 and Ctrl 2 was labeled at 5‘ end (DC 12_5‘ and Ctrl 2_5‘) and 3‘ end (DC 12_3‘ and Ctrl 
2_3‘) with ATTO 647N. C+D) DC 12.53 and DC 12.53sc1 was labeled at 5‘ end (5‘_DC 12.53 and 
5‘_DC 12.53sc1) and 3‘ end (3‘_DC 12.53 and 3‘_DC 12.53sc1) with ATTO 647N.4×10
5
 THP-1 cells 
were incubated with 250 nM of 3‘and 5‘-ATTO 647N-labeled aptamers at 37°C for 10 minutes. A and 
C) The percentage of cells bound by aptamers and B and D) relative MFI (aptamer/control) were 
measured by flow cytometry (A+B) n=4, C+D) n=2, mean ± SD). 
 
4.2.4   Internalization of aptamers by J774A.1 cells 
The aim of the current study was to use DC 12 aptamer as a delivery vehicle. The 
aptamer must be internalized into the cells in order to become an appropriate 
delivery vehicle. It was therefore of great importance to test the internalization ability 
of DC 12 and DC 12.53. Confocal microscopy was used to investigate the 
internalization of labeled aptamers. 2x105 J774A.1 cells were incubated at 37°C for 
10 minutes with ATTO 647N-labeled aptamers. The cells were fixed with 4% 
paraformaldehyde. The cell membrane was stained with the wheat germ agglutinin 
(WGA) - Alexa fluor 488, which is a membrane marker and the nuclei was stained 
with 4‘,6-diamidino-2-phenylindole (DAPI). The slides were prepared and kept 
overnight. The next day, confocal microscopy images of single cells were acquired 
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at various depths (Z-stacks). The incubation time of 10 minutes was chosen in 
accordance with the time used in the selection of these aptamers. DC 12 and DC 
12.53 signals were observed in almost every cell (Figure 4.2.9). The red channel 
was used to acquire the aptamer signal (ATTO 647N-signal), while, less than 2-4 % 
of cells showed control aptamers signal. 
 
Figure 4.2.9: Internalization of aptamers into J774A.1 cells 
2×10
5
 J774A.1 were incubated with 250 nM aptamers-ATTO 647N-labeled for 10 min, fixed and co-
stained with the membrane marker WGA-Alexa Fluor 488 and nuclear marker DAPI. In laser 
scanning microscopy (LSM), pictures along the Z-axis were taken (Z numbers are given in μm). A) 
DC 12 B) Ctrl 2 C) DC 12.53 D) DC 12.53sc1.Experiment was performed in duplicate with two 
independent repeats. 10 pictures of the Z axis were taken from single cell and 8 high dense fields 
from the slides were selected from all samples. 
 
4.2.6   Binding of aptamers to human primary and TPP 
macrophages 
As described in the previous section, DC 12 and DC 12.53 have the potential to bind 
to BM-DCs, J774A.1, and THP-1 cells. DC 12 and DC 12.53 were intended to be 
used as a delivery vehicle to target both human baseline and TPP macrophages. 
The binding of aptamers to human baseline and TPP macrophages was investigated 
Results 
55 
 
for that purpose.  TPP macrophages were differentiated from human baseline 
macrophages. CD14+ monocytes were sorted from the PBMC using the CD14+ 
magnetic beads according to the manufacturer protocol. CD14+ monocytes were 
differentiated in the presence of GM-CSF for three days into the baseline 
macrophages (Figure 4.2.10). After three days, the medium was replaced with fresh 
medium containing GM-CSF plus stimulants TPP (TNF, PGE2, and TLR2 Ligand) for 
the next three days (Figure 4.2.10). 
 
Figure 4.2.10:  Schematic representation of isolation and differentiation of TPP macrophages 
CD14+ monocytes were isolated from the buffy coats and differentiated into the baseline 
macrophages in the medium supplemented with GM-CSF for three days. The medium was replaced 
by fresh medium supplemented with GM-CSF plus TPP (TNF, PGE2, and TLR2 Ligand) stimulants for 
the next three days. (Protocol and differentiation scheme taken from Xue et al.
114
). 
 
Baseline macrophages have also been differentiated into two other phenotypes IFN-
ɤ and IL-4. Surface markers CD14, CD25, CD23, and CD86 were analyzed as 
described above114.  
Table 4-10: MFI of surface markers (CD23, CD86, CD25, and CD14) of different macrophage 
phenotypes in flow cytometry  
Macrophage Phenotype MFI 
CD23 CD86 CD25 CD14 
Mb 19.20±3.56 69.3±11.7 3.05±0.44 84.2±27.9 
IL-4 192.0±45.8 53.5±16.4 2.42±0.44 26.5±7.98 
IFN-ɤ 23.0±9.14 223±72.9 2.98±0.69 60.0±20.1 
TPP 23.4±7.17 47.4±15.6 7.40±0.44 213±56.6 
 
CD14 and CD25 have high upregulated surface markers for the TPP chronic 
inflammatory macrophages (Table 4-10 and Figure 4.2.11C,D). CD 23 was the 
highly upregulated surface marker for the IL-4 activated macrophages (Table 4-10 
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and Figure 4.2.11A). CD86 was the highly upregulated surface marker for the IFN-ɤ 
activated macrophages (Table 4-10 and Figure 4.2.11B). 
 
Figure 4.2.11: Phenotypic characterization of macrophages differentiated with IFN-ɤ, IL-4, and 
TPP (TNF, PGE2, and TLR2 Ligand)  
Flow cytometry of CD14, CD25, CD23, and CD86 in Mb (baseline macrophages), IFN-ɤ, IL-4, and 
TPP activated macrophages. MFI of one experiment in duplicate (n=3, mean ± SD). 
 
The flow cytometry assay analyzed the binding of aptamers to the human primary 
baseline (Table 4-11 and Figure 4.2.12) and TPP macrophages (Table 4-12 and 
Figure 4.2.13). 
Table 4-11: % Human primary macrophages bound by ATTO 647N-labeled aptamers and 
relative MFI in flow cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2* 4.38±0.09 1.00±0.01 
DC 12 97.0±1.04 14.2±1.03 
DC 12.53 98.2±0.75 14.2±6.24 
DC 12.53sc1** 4.81±1.15 1.00±0.01 
DC 12.53sc2 2.20±0.88 0.78±0.14 
 *control for DC 12 
 **control for DC 12.53 and DC 12.53sc2 
 
5‘-ATTO 647N-labeled Ctrl 2, DC 12, DC 12.53, and DC 12.53sc1 were incubated 
with 4x105 cells in the VLE RPMI 1640 medium supplemented with 10% FCS for 10 
minutes at 37°C.  
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Figure 4.2.12:  Binding of the aptamers to human primary baseline macrophages 
4×10
5
 human primary baseline macrophages were incubated with 250 nM of 5‘-ATTO 647N-labeled 
aptamers at 37°C for 10 minutes. A) The percentage cells bound by aptamers and B) relative MFI 
(aptamer/control) were determined by flow cytometry (n=2, mean ± SD). 
 
The percentage of cells bound by DNA and MFI was detected by flow cytometry. DC 
12 and DC 12.53 have the potential to bind to human primary baseline and TPP 
macrophages. 
Table 4-12: % TPP macrophages bound by ATTO 647N-labeled aptamers and relative MFI in 
flow cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2* 8.06±0.8 1.0±0.01 
DC 12 59±4.2 9.1±4.08 
DC 12.53 64.6±5.9 11.8±3.7 
DC 12.53sc1** 7.29±1.65 1.0±0.04 
 *control for DC 12 
 **control for DC 12.53 
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Figure 4.2.13:  Binding of the aptamers to TPP macrophages 
 4×10
5
 TPP macrophages were incubated with 250nM of 5‘-ATTO 647N-labeled aptamers at 37°C for 
10 minutes. A) The percentage cells bound by aptamers and B) relative MFI (aptamer/control) were 
determined by flow cytometry (n=2, mean ± SD). 
 
4.2.7   Internalization of aptamers by primary human 
baseline macrophages 
As described in Section 4.2.4, DC 12 and DC 12.53 have the ability to internalize 
into J774A.1 cells. These aptamers to be used as a delivery vehicle in the study in 
hand, to deliver antagomir 125a-5p into the human baseline macrophages, so the 
internalization ability of DC 12 and DC 12.53 aptamer into human baseline 
macrophages was investigated.  
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Figure 4.2.14: Internalization of aptamers into human baseline macrophages  
2×10
5
 human baseline macrophages were incubated with 250 nM aptamers-ATTO 647N labeled for 
10 min, fixed and costained with the membrane marker WGA-Alexa Fluor 488 and nuclear marker 
DAPI. In LSM, pictures along the Z-axis were taken (Z numbers are given in μm). A) DC 12 B) Ctrl 2 
C) DC 12.53 D) DC 12.53sc1.Experiment was performed in duplicate with two independent repeats.  
 
Confocal microscopy was used to investigate the internalization of labeled aptamers. 
With ATTO 647N-labeled aptamers, 2x105 three days differentiated human baseline 
macrophages were incubated at 37°C for 10 minutes. The cells were fixed with 4% 
paraformaldehyde. The cell membrane was stained with WGA-Alexa fluor 488, 
which is a membrane marker, while the nuclei was stained with DAPI. The slides 
have been prepared and kept overnight. Next day, confocal microscopy images of 
single cells were acquired at various depths (Z-stacks). The DC 12 and DC 12.53 
signals were observed in almost every cell (Figure 4.2.14). The second image of 
each aptamer was only the red signal acquired for the aptamer in the microscopy. 
However, less than 2-4 % of cells showed control aptamers signal. 
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4.3   Characterization of antagomir 125a-5p in J774A.1 cells 
The aim of the project was to use a macrophage-binding aptamer as a delivery tool 
to deliver antagomir 125a-5p in human baseline macrophages. miRNA 125a-5p is 
highly upregulated in TPP macrophages (Figure 3.2.3). It could have an impact on 
the overall polarization state of the TPP macrophages. In the previous section 
(Section 4.2), DC 12 aptamer was characterized for its binding and internalizing 
properties towards J774A.1 and human baseline macrophages. Before the 
construction of aptamer-antagomir 125a-5p conjugates (aptamiR 125a-5p chimera), 
it was worthwhile to investigate the affinity and specificity of antagomir 125a-5p 
towards miRNA 125a-5p in the cells. The EGFP reporter gene and a stable cell line 
were used for the functional validation of antagomir 125a-5p. 
 
4.3.1   Construction of the reporter gene EGFP-4X 125a-5p 
for validation of antagomir function 
miRNA are basically small non-coding RNAs that are generally 18-25 nucleotides in 
the length. The expression of multiples genes is regulated by a single miRNA 
through a complementary nucleotide sequence that binds to the 3‘ UTR195-197. The 
pEGFP-N1 report plasmid was used to validate loss-of-function and gain-of-function 
studies for miRNA. The most beneficial function of the EGFP plasmid is the 
visualization and quantification of the green fluorescent protein when transfected into 
the cells.  Therefore, the 4X miRNA 125a-5p target site was cloned into the 3‘ UTR 
of mRNA of an EGFP encoding plasmid (Figure 4.3.1A) as described previously by 
Pofahl et al.28 for miRNA 21.  The transfection of the plasmid into the eukaryotic cells 
leads to the transcription of the EGFP mRNA with 4X miRNA 125a-5p target sites at 
the 3‘UTR. These target sites have helped to determine the status of endogenous 
miRNA 125a-5p in the cells.  The presence of miRNA 125a-5p interacts with the 4X 
miRNA 125a-5p target sites due to Watson Crick base pairing and therefore the 
translation of EGFP protein is inhibited (Figure 4.3.1B). The interaction between 
miRNA and the target site can be prevented by antagomir 125a-5p (Figure 4.3.1C). 
The antagomir is modified RNA and has a high binding affinity to their respective 
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miRNA198. Thus, miRNA interacts with the antagomir, consequently, the EGFP 
mRNA is translated into protein. The EGFP protein can be visualized through 
confocal microscopy and quantified by flow cytometry.  
 
Figure 4.3.1: Schematic representation of the EGFP reporter gene functioning  
A) EGFP-4X 125a-5p reporter gene structure B) The presence of miRNA 125a-5p interacts with 
mRNA of the EGFP leading to inhibition of the translation C) The interaction of miRNA 125a-5p with 
mRNA of EGFP is blocked by antagomir 125a-5p (modified from Pofahl Ph.D. thesis
28
).  
 
4.3.2   Functional verification of the reporter gene through 
miRNA 125a-5p mimic 
The functional verification of the reporter gene EGFP-4X 125a-5p was performed by 
using miRNA 125a-5p mimic. J774A.1 cells were cotransfected with the reporter 
gene in combination with the miRNA 125a-5p mimic or with the control miRNA 
mimic.  The control plasmid without 4X miRNA 125a-5p target sites was also used in 
combination with the miRNA 125a-5p mimic or with the control miRNA mimic. 
Different concentrations of the miRNA 125a-5p mimic and control mimic were used 
for the functional verification of the reporter system. After cotransfection, the flow 
cytometry was used to measure the MFI after 24 hours (Figure 4.3.2 and Figure 
4.3.3). The effect of miRNA 125a-5p mimic was only observed in the reporter gene 
EGFP-4X 125a-5p due to the interaction of miRNA 125a-5p mimic with target sites 
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on the mRNA of EGFP (Figure 4.3.3). This interaction leads to the inhibition of 
green fluorescent protein.The control mimic did not show any effect (Figure 4.3.3). 
The transfection of the control plasmid in combination with miRNA 125a-5p mimic or 
control mimic had no effect on the inhibition of the green fluorescent protein (Figure 
4.3.2).  
 
Figure 4.3.2: Transient transfection of miRNA 125a-5p mimic and control mimic with control 
plasmid (CP) 
1×10
5
 J774A.1 cells were seeded one day before transfection. 500 ng CP was transiently transfected 
with miRNA 125a-5p mimic and control mimic at different concentrations (1 nM – 10 nM). Black bar 
represents only 500 ng CP, white bars represents 500 ng CP transfected with miRNA 125a-5p mimic 
(1 nM – 10 nM), and grey bars represents 500 ng CP transfected with control miRNA mimic (1 nM – 
10 nM). After, 24 hours, the cells were scraped and washed with 1 ml DPBS. The EGFP expression 
was measured by flow cytometry. The experiment was performed twice (mean ± SD).  
 
It was thus proven that miRNA 125a-5p mimic had a strong influence on the reporter 
gene EGFP-4X 125a-5p and the 4X target sites of miRNA 125a-5p were functional. 
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Figure 4.3.3: Transient transfection of miRNA 125a-5p mimic and control mimic with the target 
site plasmid (4X 125a-5p) 
1×10
5
 J774A.1 cells were seeded one day before transfection. 500 ng 4X 125a-5p was transiently 
transfected with miRNA mimic and control mimic at different concentrations (1 nM – 10 nM). Black 
bar represents only 500 ng 4X 125a-5p, white bars represents 500 ng 4X 125a-5p  transfected with 
miRNA 125a-5p mimic (1 nM – 10 nM), and grey bars represents 500 ng 4X 125a-5p  transfected 
with control miRNA mimic (1 nM – 10 nM). After, 24 hours, the cells were scraped and washed with 1 
ml DPBS. The EGFP expression was measured by flow cytometry. The experiment was performed 
twice (mean ± SD).  
  
Next, a stable cell line was constructed for the transfection independent experiments 
and for the permanent integration of the EGFP reporter gene into the cells. 
 
4.3.3   Generation of stable J774A.1 cell line with the EGFP-
4X 125a-5p reporter gene 
In the previous sections (Section 4.3.1 and Section 4.3.2), the EGFP-4X 125a-5p 
reporter gene was constructed and functional verification was performed through 
transfection. The generation of EGFP-4X 125a-5p stable cell line was essential for 
the transfection independent experiments for aptamer guided delivery of antagomir 
125a-5p and for the permanently integrated EGFP plasmid with the 4X 125a-5p 
target site.  For this purpose, 2 µg of the EGFP-4X 125a-5p plasmid was transfected 
into the J774A.1 cells. The plasmid has a geneticin (G418) resistance gene. 
Therefore, the selection of cells was based on the G418 gene. Cells without a 
resistance gene were unable to survive in cell culture medium supplemented with 
300 µg/ml G418 antibiotic. After four weeks, the cells were sorted according to the 
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EGFP expression as monoclonal cells using the cell sorting flow cytometry. Cells 
with the EFGP expression were sorted in the 96-well plates (single cell/well) and 
grown in the normal cell culture conditions, DMEM medium supplemented with 10% 
FCS, 300 µg/ml G418.  
 
4.3.4   Antagomir 125a-5p inhibits endogenous miRNA 
125a-5p in stable cell line J774A.1 miRNA 125a-5p 
In the previous section (Section 4.3.3), the stable cell line was constructed using the 
reporter gene. The functional validation of the stable cell line, the mode of action of 
antagomir 125a-5p, and the endogenous status of miRNA 125a-5p were 
investigated through antagomir 125a-5p transfection. As a control, a stable cell line 
with control plasmid without target sites was also constructed in the same way as 
the EGFP-4X 125a-5p stable cell line. A control antagomir sequence was also used 
from the earthworm, which has no target gene in both human and mouse species. 
Stable cell lines were transfected with the antagomir 125a-5p and control antagomir. 
After 48 hours of transfection, the transfection of antagomir 125a-5p induced an 
increase in the MFI of the EGFP-4X 125a-5p stable cell line, while the control 
antagomir did not affect the MFI (Figure 4.3.5). The control stable cell line had no 
effect either with the antagomir 125a-5p or the control antagomir (Figure 4.3.4).  
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Figure 4.3.4: Transfection of antagomir 125a-5p and control antagomir  
4×10
4
 control stable cell line J774A.1 cells were seeded one day before transfection. Antagomir 
125a-5p and control antagomir had been transfected at three different concentrations. After, 48 
hours, the cells were scraped and washed with 1 ml DPBS. The EGFP expression was measured by 
flow cytometry. The experiment was performed twice (mean ± SD). 
 
As a result, the transfection of antagomir 125a-5p in the EGFP-4X 125a-5p stable 
cell line resulted in an interaction of antagomir 125a-5p with an endogenous miRNA 
125a-5p, so that miRNA 125a-5p did not interact with the mRNA of EGFP. There 
was an increase in the translation of the EGFP protein, which induced MFI. 
Therefore, the transfection of antagomir 125a-5p inhibited the endogenous miRNA 
125a-5p, as expected.  
 
Figure 4.3.5: Transfection of antagomir 125a-5p and control antagomir  
4×10
4
 EGFP-4X 125a-5p stable cell line J774A.1 cells were seeded one day before transfection. 
Antagomir 125a-5p and control antagomir had been transfected at three different concentrations. 
After, 48 hours, the cells were scraped and washed with 1 ml DPBS. The EGFP expression was 
measured by flow cytometry. The experiment was performed twice (mean ± SD).  
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Thus, it was shown that the stable cell line J774A.1 miRNA 125a-5p had a certain 
level of the endogenous miRNA 125a-5p which could be inhibited by antagomir 
125a-5p. Thus, this stable cell line was used in transfection independent 
experiments with aptamiR 125a-5p.  
Next, the binding of the aptamers was analyzed for the stable cell line J774A.1 
miRNA 125a-5p. 
 
4.3.5   Binding of aptamer to the stable cell line J774A.1 
miRNA 125a-5p 
The stable cell line has a reporter gene, which is permanently integrated into the 
cell‘s genome. This gene could have an impact on the overall machinery of the cells 
including the endogenous DNA, RNA, proteins, and surface proteins or on the target 
of the aptamer on the cell surface. The binding of the aptamer was investigated with 
the stable cell line, to elucidate that the reporter gene did not affect the binding of the 
aptamer. 
Table 4-13: % stable cell line J774A.1 miRNA 125a-5p cells bound by ATTO 647N-labeled 
aptamers and relative MFI in flow cytometry binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2* 15.5±1.1 1.0±0.04 
DC 12 96.7±0.7 4.0±0.33 
DC 12.53 93.0±2.9 4.2±0.10 
DC 12.53sc1** 15.9±1.2 1.0±0.02 
 *control for DC 12 
 **control for DC 12.53  
 
5‘-ATTO 647N- labeled Ctrl 2, DC 12, DC 12.53, and DC 12.53sc1 were incubated 
with 4x105 cells in the DMEM medium supplemented with 10% FCS for 10 minutes 
at 37°C. The percentage of cells bound by DNA and MFI was detected by flow 
cytometry. All of the selected aptamers showed binding to the stable cell line (Table 
4-13 and Figure 4.3.6).  
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Figure 4.3.6:  Binding of the aptamers to the stable cell line J774A.1 miRNA 125a-5p 
 4×10
5
 stable cell line J774A.1 miRNA 125a-5p were incubated with 250 nM of 5‘-ATTO 647N-labeled 
aptamers for 10 minutes at 37°C. A) The percentage cells bound by aptamers and B) relative MFI 
(aptamer/control) were measured by flow cytometry (n=2, mean ± SD). 
 
Therefore, it was evident that the reporter gene did not affect the binding potential of 
aptamers. 
 
4.4   Synthesis and pharmacological characterization of 
aptamer-antagomir 125a-5p conjugates (aptamiR 125a-5p) 
4.4.1   Coupling of aptamers and antagomir 125a-5p  
As described in the Section 4.2.3, 3‘ end of the aptamer DC 12 did not influence the 
binding capability of the aptamer. Thus, the 3‘ end of the DC 12 aptamer was 
conjugated with the 5‘-maleimide antagomir 125a-5p, to form a chimera known as 
DC 12 aptamiR 125a-5p. Similarly, 3‘ end of the Ctrl 2 aptamer was conjugated with 
the 5‘-maleimide antagomir 125a-5p, to form a chimera known as Ctrl 2 aptamiR 
125a-5p.  The 5‘-maleimide antagomir 125a-5p was conjugated through thiol-
maleimide chemistry to the 3‘-thiol-C6 aptamer sequences (DC 12 and Ctrl 2). Thiol-
modified aptamers and maleimide-modified antagomir 125a-5p were deprotected 
separately and then mixed in DPBS, for 24 hours. Maleimide has the property to 
react with the sulfhydryl groups and thus to form a stable thioether linkage (Figure 
4.4.1).   
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Figure 4.4.1: Overview of thiol-maleimide reaction to synthesize aptamiR 125a-5p 
3‘modified aptamer was coupled to 5‘modified antagomir via thiol-maleimide chemistry (modified from 
Silvana Ph.D. thesis
101
). 
After 24 hours, 4% agarose gel was run to visualize the required product size 
(Figure 4.4.2). 
 
Figure 4.4.2: 4% agarose gel for confirmation of required product size  
Ctrl 2 (79 bases), DC 12 (80 bases), Ctrl 2 conjugate (79+24 =103 bases) and DC 12 conjugate 
(80+24 =104 bases). The smaller bands in the conjugated lines are unconjugated aptamers, which 
were removed by using 15% PAGE gel. 
 
Following confirmation of 4% agarose gel, the chimeras were purified using 15% 
PAGE gel and the concentration was measured using nanodrop 2000. They were 
then characterized by their ability to bind to macrophages. 
 
4.4.2   Binding capability of DC 12 aptamiR 125a-5p 
The conjugation of DC 12 aptamer with an antagomir 125a-5p may influence the 
interaction properties of the aptamer with the cells. It may be possible that the 
aptamer did not fold in the correct conformation, required to bind to the cells.  
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Table 4-14: % cells bound by ATTO 647N-labeled aptamers and relative MFI in flow cytometry 
competition binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
              Ctrl 2* 7.01±8.98 1.0±0.12 
 
 
DC 12+ 
 
No competition 63.4±9.23 2.84±0.4 
UN-L DC 12 40.3±7.17 2.13±0.4 
UN-L Ctrl2 65.5±7.28 2.77±0.4 
DC 12 aptamiR 42.1±5.10 2.19±0.2 
CTRL 2 aptamiR 67.7±8.12 2.84±0.2 
*control, UN-L= unlabeled (without fluorophore) 
UN-L DC 12 (unlabeled DC 12 aptamer), UN-L Ctrl 2 (unlabeled ctrl 2), DC 
12 aptamiR (DC 12 aptamer conjugated with antagomir 125a-5p), Ctrl 2 
aptamiR (ctrl 2 conjugated with antagomir 125a-5p) 
 
To investigate the binding ability of the aptamiR, a competitive binding assay was 
performed (Table 4-14 and Figure 4.4.3). 
8x104 THP-1 cells were co-incubated with 50 nM ATTO 647N-labeled aptamers and 
eight-fold molar excess unlabeled aptamers (without fluorophore) and aptamiR 
125a-5p in RPMI 1640 supplemented with 10% FCS at 37°C for 10 minutes. The 
percentage of cells bound to the labeled DC 12 was decreased in the presence of 
unlabeled DC 12 and DC 12 aptamiR 125a-5p. Whereas, no competition was 
observed in the presence of unlabeled Ctrl 2 and Ctrl 2 aptamiR 125a-5p. Ctrl 2 
aptamiR 125a-5p had functional antagomir 125a-5p domain but Ctrl 2 aptamer 
domain was not functional and could not bind to the cells. Hence, DC 12 aptamiR 
125a-5p retains the binding properties with the cells and may be able to deliver 
antagomir 125a-5p. 
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Figure 4.4.3: Binding capability of aptamiR 125a-5p is maintained 
8×10
4
 THP-1 cells were incubated with 50 nM ATTO 647N-labeled DC 12 in the presence of 400 nM 
competitors (grey bars) and analyzed by flow cytometry (n=2, mean ± SD). UN-L DC 12 represents 
unlabeled DC 12 aptamer, UN-L Ctrl 2 represents unlabeled Ctrl 2 aptamer, DC 12 aptamiR 
represents DC 12 conjugated with antagomir 125a-5p, and Ctrl 2 aptamiR represents Ctrl 2 
conjugated with antagomir 125a-5p. 
 
4.4.3   Transfection of aptamiR 125a-5p 
The conjugation of aptamer with the antagomir 125a-5p may influence the 
interaction properties of the antagomir 125a-5p with an endogenous miRNA 125a-
5p. It may be possible that the folding or size of aptamer domain limits the 
interaction of antagomir 125a-5p with the miRNA. The transfection of aptamiR 125a-
5p was performed to investigate the interaction of antagomir 125a-5p with miRNA. 
AptamiR 125a-5p were transfected in the stable cell lines, control stable cell line and 
EGFP-4X 125a-5p stable cell line. Different controls were included in the 
experiments such as DC 12 and Ctrl 2 un-conjugated, antagomir 125a-5p and 
antagomir control. A concentration of 50 nM was selected as it showed significant 
increase in the EGFP expression (Figure 4.3.5). 
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Figure 4.4.4: Transfection of aptamiR 125a-5p (Ratio of MFI) 
4×10
4
 control stable cell line (light grey bars) EGFP-4X 125a-5p stable cell line (black bars) cells were 
seeded one day before transfection. AptamiR 125a-ap and controls (50 nM) were transfected using 
lipofectamine 2000. After, 48 hrs cells were scraped and washed with 1 ml DPBS. The ratio of MFI 
was measured by flow cytometry. The experiment was performed twice (n=2, mean ± SD).  
 
The cells were transfected with aptamiR 125a-5p and controls. After 48 hours of 
transfection, DC 12 and Ctrl 2 aptamiR 125a-5p with the functional antagomir 125a-
5p showed an increase in MFI and also an increase in the EGFP expressing cells in 
the EGFP-4X 125a-5p stable cell line (Figure 4.4.4 and Figure 4.4.5). The 
antagomir 125a-5p did not have similar effect when compared to the conjugated 
antagomir 125a-5p, which could be due to the transfection efficiency of the small 
RNAs with lipofectamine 2000. This problem could be encountered or avoided by 
using a transfecting agent for small RNAs. The aptamiR 125a-5p showed an 
increase in MFI and EGFP expressing cells in the control stable cell line. This effect 
could be due to the non-specific effect of aptamiR 125a-5p  and it could be 
considered as non-significant compared to the EGFP-4X 125a-5p stable cell line 
(Figure 4.4.4 and Figure 4.4.5).  
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Figure 4.4.5: Transfection of aptamiR 125a-5p (Ratio of EGFP expressing cells) 
4×10
4
 control stable cell line (light grey bars) EGFP-4X 125a-5p stable cell line (black bars) cells were 
seeded one day before transfection. AptamiR 125a-5p and controls (50 nM) were transfected using 
lipofectamine 2000. After, 48 hours, the cells were scraped and washed with 1 ml DPBS. EGFP 
expressing cells were measured by flow cytometry. The experiment was performed twice (n=2, mean 
± SD).  
 
The antagomir 125a-5p domain of the aptamiR 125a-5p has thus been shown to 
retain its interaction properties with the miRNA. The aptamer domain did not affect 
the functionality of the antagomir 125a-5p after the conjugation. 
 
4.4.4   Effect of aptamiR 125a-5p on the reporter gene 
expression 
The functionality of aptamiR 125a-5p was tested in Section 4.4.2 and Section 4.4.3 
above. In order to investigate the ability of DC 12 aptamer to deliver antagomir 125a-
5p into the cytoplasm, aptamiR 125a-5p was incubated with the EGFP-4X 125a-5p 
stable cell line.  DC 12 aptamiR 125a-5p and Ctrl 2 aptamiR 125a-5p were diluted in 
the cell culture medium and incubated with a reporter gene stable cell line. As a 
positive control 50 nM of aptamiR 125a-5p was also transfected using lipofectamine 
2000 (Section 4.4.3). 
Results 
73 
 
 
Figure 4.4.6: Aptamer-targeted delivery of antagomir 125a-5p in stable cell line 
4×10
4
 EGFP-4X 125a-5p stable cell line (black bars) cells were seeded one day before aptamer-
antagomir 125a-5p incubation and transfection. AptamiR 125a-5p (500 nM) were incubated and 
positive controls (50 nM) were transfected using lipofectamine 2000. After, 48 hrours, the cells were 
scraped and washed with 1 ml DPBS. A) The MFI and B) EGFP expressing cells were measured by 
flow cytometry. The experiment was performed twice (n=2, mean ± SD).  
 
After 48 hours, the cells were scraped and washed with 1 ml of DPBS. The MFI of 
the cells and the percentage of EGFP expressing cells were determined using flow 
cytometry. Incubation with DC 12 aptamiR 125a-5p and Ctrl 2 aptamiR 125a-5p 
showed no increase in the EGFP expression compared to untreated cells (Figure 
4.4.6). Transfection of the aptamiR 125a-5p showed an increase in the MFI and an 
increase in the percentage of EGFP expressing cells. It meant that the DC 12 
mediated delivery of antagomir 125a-5p into the cytoplasm was limited. It might be 
possible that the aptamiR 125a-5p are entrapped in the endosomal or lysosomal 
compartments. 
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4.4.5   Pharmacological effects of aptamiR 125a-5p on 
human baseline macrophages 
DC 12 aptamer was able to recognize and bind to both human baseline and TPP 
macrophages (Figure 4.2.12 and Figure 4.2.13). The main distinct property of the 
TPP macrophage phenotype was the upregulation of miRNA 125a-5p (see Figure 
3.2.3 in the introduction section). DC 12 aptamer was successfully conjugated with 
the antagomir 125a-5p (Section 4.4.1) to inhibit miRNA 125a-5p. The domains of 
DC 12 aptamiR 125a-5p were functional in terms of targeting macrophages and 
inhibiting miRNA 125a-5p via transfection in the reporter gene assay (Section 4.4.2 
and Section 4.4.3). Unfortunately, DC 12 guided uptake of aptamiR 125a-5p did not 
show any effect on the EGFP expression on the stable cell line. Non-effected 
expression may be due to the entrapment of the antagomir in the endosomes or 
lysosomes (Figure 4.4.6). It may be possible that the human baseline macrophages 
have different uptake pathways for DC 12 or that they might not have sufficient 
endosomes for entrapment of DC 12. 
Table 4-15: MFI of surface markers (CD23, CD86, CD25, and CD14) of different macrophage 
phenotypes and TPP treated groups in flow cytometry  
Macrophage Phenotype MFI 
CD23 CD86 CD25 CD14 
Mb 49.6±1.98 68.2±1.95 6.5±0.43 155±2.06 
IL-4 250±93.5 20.3±9.37 5.9±0.37 37.5±3.63 
IFN-ɤ 57±0.83 233±113 7.42±1.25 89.6±3.99 
 
 
TPP+ 
No treatment 63.5±0.55 62.7±7.96 32±2.69 353±195 
DC 12 (500nM) 59.1±0.95 57±11.7 27.4±3.05 376±198 
Ctrl 2 (500nM) 60.5±1.45 59.9±8.46 29.5±2.28 384±215 
Ctrl 2 aptamiR (500nM) 58.6±0.38 61.4±10.9 27.4±4.76 381±190 
DC 12 aptamiR (500nM) 57.4±1.84 75.4±24.3 30±3.54 395±237 
  
In order to investigate inhibition of upregulated miRNA 125a-5p in TPP 
macrophages through DC 12 aptamiR 125a-5p, baseline macrophages were 
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incubated with aptamiR 125a-5p. 500 nM aptamiR 125a-5p, DC 12, and Ctrl 2 
unconjugated have been incubated with the human baseline macrophages for 30 
minutes under standard cell culture conditions. Then, the supernatant was replaced 
with fresh medium containing TPP macrophage stimulants. As the control baseline, 
IL-4, and IFN-ɤ macrophage stimulants were also incubated with baseline 
macrophages for the next three days. The cells were stained with surface marker 
antibodies (CD14, CD25, CD23, and CD86) and the MFI was measured using flow 
cytometry.   
 
Figure 4.4.7: Aptamer-targeted delivery of antagomir 125a-5p in human baseline macrophages 
4×10
6
 human baseline macrophages were treated with aptamiR 125a-5p for 30 minutes. Then, the 
medium was replaced with fresh medium containing TPP stimulants. As positive control, untreated 
cells, IL-4, and IFN-ɤ macrophages were also differentiated for the next three days. After 72 hours, 
cell surface markers profiles were determined through flow cytometry (n=2, mean ± SD).  The 
treatment of 500 nM DC12 aptamiR (DC 12 aptamer-antagomir 125a-5p) showed similar MFI 
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compared to untreated TPP macrophages, Ctrl 2 aptamiR (Ctrl 2 aptamer-antagomir 125a-5p), DC 12 
(unconjugated DC 12), and Ctrl 2 (unconjugated Ctrl 2). 
 
The expression level of TPP stimulated macrophages showed similar MFI 
regardless of treatment (Table 4-15 and Figure 4.4.7). The results were consistent 
with the previous experiments of the reporter gene (Figure 4.4.6). The entrapment 
of DC12 aptamiR 125a-5p limited its interaction with the endogenous miRNA 125a-
5p. 
 
4.5   Aptamer-targeted activation of CD8 T cells 
In the previous sections of this chapter, DC 12 aptamer was selected from the NGS 
data of BM-DCs cell-SELEX. DC 12 aptamer was shown to binds to J774A.1, THP-
1, human baseline macrophages, and dendritic cells. DC 12 aptamer has also been 
internalized into J774A.1 and human baseline macrophages and be non-
immunogenic. DC 12 aptamer meets all requirements to function as a suitable 
carrier molecule.  
 In the last Section 4.4, DC 12 aptamer was successfully conjugated with antagomir 
125a-5p for endogenous inhibition of miRNA 125a-5p and its functionality was 
tested. Unfortunately, DC 12 aptamer guided delivery of antagomir 125a-5p may 
have entraped into the endosomes and limited its inhibitory activity. Therefore, the 
carrier properties of DC 12 aptamer was further illustrated by an OVA model system. 
This system was widely used and most feasible model to study aptamer-based 
delivery of antigenic OVA peptides to DCs for T cell-mediated immunity101. It is well 
known that OVA possesses binding sites MHC I OVA257-264 (MHC I peptide) and 
MHC II OVA323-339 (MHC II peptide)
199,200. Transgenic mouse models were 
established to produce OVA-specific CD8 or CD4 T cells. These models produce 
either CD8 T cells that identify MHC I bound OVA257-264 or CD4 T cells that recognize 
MHC II bound OVA323-339
201,202.  
Isolated MHC I or MHC II peptides are capable of binding to MHC molecules 
expressed on the cell surface. Thus, DC 12 aptamer was conjugated with prolonged 
OVA peptide (OVA249-272, known as OT-I peptide), expanded with MHC I recognition 
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sequence for targeted delivery to DCs for targeted activation of CD8 T cells. OT-I 
peptide was covalently bound to DC 12 aptamer by thiol-maleimide chemistry. 
  
4.5.1   Coupling of aptamers and OT-I (OVA249-272) peptide 
5‘ thiol-modified aptamers were conjugated through thiol-maleimide chemistry to 
MHC I- restricted OT-I OVA peptide. Aptamers modified with 5‘-thiol were reduced to 
thiol derivatives and mixed with N-terminal maleimide MHC I-restricted OVA peptide. 
Maleimide has the ability to react with the sulfhydryl groups and forms a stable 
thioether linkage (Figure 4.5.1B).   
 
Figure 4.5.1: Overview of thiol-maleimide reaction to synthesize aptamer-OT-I (OVA249-272) 
conjugates 
A) MHC I peptide OVA 257-264 is highlighted in the box. The OVA peptide expanding MHC I recognition 
sequence was used for coupling with aptamers. B) 5‘ thiol-modified aptamer was coupled to N-
terminal maleimide functionalized peptide (yellow star) (Figure modified from Silvana Ph.D.  
thesis
101
). 
 
Reverse phase high performance liquid chromatography (RP-HPLC) was performed 
to purify the conjugates. 
 
4.5.2   Aptamer-targeted delivery of OT-I peptide for CD8 T 
cells activation 
In order to investigate aptamer-OT-I conjugates mediated targeted activation of CD8 
T cell, an in vitro proliferation assay was selected. This assay was established by Dr. 
Silvana Haβel in LIMES, University of Bonn, Germany for the aptamer-targeted 
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activation of T cells101 and was also performed by Dr. Silvana Haβel, University of 
Bonn, Germany.  Genetically modified murine OVA-specific CD8 T cells203 were able 
to recognize OVA257-264 presented on MHC I molecules on the cell surface of BM-
DCs.  Briefly, 5x104 murine BM-DCs cells were counted and treated with either MHC 
I or OT-I peptides and aptamer-OT I conjugates in the DC cell medium at 37°C for 
10 minutes. As a positive control, D#7 aptamer conjugated with OT-I was used, a 
known activator of CD8 T cell101. D#7 aptamer was selected and characterized by 
Dr. Silvana Haβel for targeted activation of T cells101. Transgenic mice were used for 
isolation of OVA-specific CD8 T cells. 1x105 cells were isolated, labeled with CFSF 
and incubated with treated BM-DCs for 72 hours.  
Carboxyfluorescein succinimidyl ester (CFSE) is considered to be an ideal dye for 
cell division measurement.  Normally, when a CFSE-treated cell proliferates, its 
daughter cells are equally endowed with dye and thus each cell division can be 
determined by analyzing the reduction of cell fluorescence through the flow 
cytometry204.CD8 T cells activation was assessed by the CFSE proliferation assay 
by flow cytometry and quantified through a ranged gate tool. 
 
Figure 4.5.2: Aptamer-targeted delivery of OT-I peptide for CD8 T cells activation 
1×10
5 
OVA-CD8 specific T cells were stained with fluorescent staining dye (CFSE) and incubated 
with 5×10
4
 BM-DCs treated with 100 nM of aptamer-conjugates, OT-I peptide and 1 nM of MHC I 
peptide. A) Black area shows non-treated cells in all histograms. CFSE profiles were determined by 
flow cytometry and the proliferated population was gated by ranged gate tool. B) The ranged gate 
percentage of CFSE T cell proliferation of triplicates (mean ± SD) was plotted (n=1 in triplicates). For 
more information see supplementary Figure S 9.3.1. The assay was performed by Dr.Silvana Haβel. 
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The black bars are non-proliferative populations (Figure 4.5.2A). This population 
was obtained by adding T cells to non-treated BM-DCs. MHC I peptide (OVA257-264) 
was able to bind directly to the MHC I molecules on the surface of BM-DCs because 
it consists only of the OVA MHC I recognition amino acid sequence (Figure 4.5.1A). 
Therefore, 1 nM MHC I peptide was able to induce strong CD8 T cells activation 
compared to 100 nM OT-I peptide, which needs to be processed by the endosomal 
compartments for presentation on the surface of BM-DCs. DC 12.53 aptamer-OT-I 
has the potential to deliver OT-I peptide and activates CD8 T cells compared to the 
D#7-OT-I (Figure 4.5.2B). As expected, Ctrl 2-OT-I and DC 12.53sc1-OT-I were 
unable to induce CD8 T cell proliferation compared to D#7-OT-I and DC 12.53-OT-I 
(Figure 4.5.2 and Figure S 9.3.1). In conclusion, DC 12.53 aptamer has the 
capability to deliver OT-I peptide into the required endosomal compartment for 
processing and presentation on the surface of BM-DCs. Upon presentation, it was 
able to induced CD8 T cell proliferation (Figure 4.5.2 and Figure S 9.3.1).  
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5   Discussion  
Aptamers are promising alternatives to protein-based target approaches as they are 
considered to have some advantages over antibodies20 (Table 5-1). Cell-targeting 
aptamers have a high specificity and affinity to their specific targets and are also 
capable of delivering cargo molecules25-29. They are cheaper, easy to synthesize, 
chemically stable, relatively smaller in size, low or non-toxic, and less immunogenic 
than other carrier molecules16-19,196. Hence, they can be used to target immune cells 
in a variety of different therapeutic and diagnostic applications. 
Table 5-1: Advantages and disadvantages of aptamers and antibodies (modified from Ganji et 
al.
205
) 
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The aim of the study is to find out whether aptamers targeting immune cells have 
been able to inhibit endogenic miRNA 125a-5p through targeted delivery of 
antagomir to macrophages. In the first phase, NGS data from BM-DCs cell-SELEX 
was used to identify the most promising sequences that will bind to J774A.1 and 
THP-1 cells, as a result, DC 12 aptamer was selected, characterized and truncated 
to 53 nucleotides. In the second phase, the EGFP reporter system and human 
baseline macrophages were used to study the inhibition of miRNA 125-5p through 
DC 12 targeted delivery of antagomir. Unfortunately, DC 12 guided uptake did not 
have sufficient effect on miRNA 125-5p inhibition. In parallel, the functionality of DC 
12 as a carrier molecule for targeted activation of CD8 T cell was tested by an OVA 
model system. Consequently, the aptamer-OT-I conjugate was found to have the 
potential to activate T cell-mediated immunity. 
 
5.1   Screening of sequences for binding to macrophages 
and DCs 
In general, cell-targeting aptamers can be obtained by using the cell-SELEX 
approach without prior knowledge of the target on the cell surface13. As described 
above, cell-targeting aptamers have certain advantages over other pharmacological 
molecules such as low toxicity, little or non-immunogenicity, easy to synthesize, no 
batch to batch variation, thermal stability, easy to modify, and internalization into the 
cells upon binding21-24,206.  
With their originally targeted cells, depending on the surface expression of aptamer-
target on other cells, the cell-SELEX related aptamers might also have the ability to 
recognize cell surface targets on other cells. For example, aptamers obtained from 
breast cancer cell-SELEX also have the ability to recognize and bind to different 
solid tumor-derived cancer cells (H460, A549, and MCF7)207. Taking this property of 
cell-targeting aptamers into account, the NGS data of BM-DCs cell-SELEX101 was 
screened to obtain aptamers targeting macrophages. The aptamers obtained from 
BM-DCs cell-SELEX have the potential to recognize and bind to DCs, which were 
subsequently used for aptamer-targeted delivery of antigen to DCs for T cells 
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activation101. In this study, the most abundant sequences from NGS data of the 10th 
selection cycle were used to screen macrophage targeting aptamers. Macrophages 
and DCs are the immune cells and latter are professional APCs. They have the 
same progenitor precursor and have overlapping properties182. Various studies have 
shown that BM-DCs, human monocyte-derived DCs, and Langerhans cells (LCs) 
have significant similarity in transcriptional level and similar ontogenetic origin with 
macrophages208. Since cell-SELEX was performed on mouse DCs it was worthwhile 
to screen these sequences with mouse macrophages.  
 
5.1.1   Binding to mouse macrophages and DCs 
BM-DCs and the mouse macrophage cell line (J774A.1) have many similar targets 
on their cell surfaces184. In this study, the most abundant sequences from the NGS 
data of BM-DCs cell-SELEX showed the potential to recognize and bind to the 
mouse macrophage cell line (J774A.1) (Figure 4.1.1 and Figure 4.1.2). DC 7, DC 
10, and DC 12 aptamers were tested in mouse macrophages and DC 12 was 
characterized to deliver antagomir 125a-5p to J774A.1 cells, expressing stable 
EGFP reporter gene and human primary baseline macrophages.  
During BM-DCs cell-SELEX, the complexity of the library decreased to 50% in the 
10th round of selection101. The selection showed enrichment of the DCs targeting 
sequences. DC 12 aptamer was also enriched in the selection procedure and was 
able to bind to BM-DCs (Figure 4.1.5 and Figure S 9.1.1). In the present work, the 
truncated version of DC 12 was used for the targeted delivery of antigen to DCs for 
the activation of CD8 T cells. Previously, the full length (80 nucleotides) D#5 and 
D#7 aptamers were used for the targeted activation of CD8 T cells101.  
 
Untill now, various DCs targeting molecules have been studied using numerous 
targeting agents to use in therapeutic purposes205. As stated in Table 5-1, aptamers 
have more advantages than antibodies, aptamer 16, generated through SELEX 
against recombinant DC-specific intercellular adhesion molecule (ICAM)-3 grabbing 
non-integrin (DC-SIGN) was as specific as anti-DC-SIGN monoclonal antibody209.  
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Cell-SELEX generated DNA aptamer pools can distinguish between mature and 
immature DCs. Later these pools were used for the discovery of biomarkers from 
DCs 210. 
   
5.1.2   Binding to human monocytes and macrophages 
As outlined in Section 3, human monocytes and macrophages have the same 
progenitors and have many similar properties as DCs. Herein, DC 12 aptamer was 
identified, which recognizes and binds to human monocytic cell line (THP-1) (Figure 
4.1.3), human primary baseline macrophages (Figure 4.2.12), and chronic 
inflammatory macrophages (TPP) (Figure 4.2.13). 
 
THP-1 cells are the most widely used cell line for the study of monocytes and 
macrophages biology, drug transport, and signaling pathways211. DC 12 aptamer 
might provide an opportunity to study these parameters in detail. As, Dou et al.212 
have shown, aptamer-drug conjugate can provide better efficacy and tolerability due 
to aptamer-targeted delivery of the drug compared to the unconjugated drug. Thus, 
DC 12 can be conjugated with drugs for the treatment of various monocytes-related 
diseases. 
THP-1 cells are also considered difficult to be transfected by non-viral approaches to 
the study of different biological processes213. Transfection of plasmids, DNA, and 
siRNA may be possible by using liposomes in combination with DC 12 aptamer, as 
liposomes provide encapsulation of therapeutic molecules and aptamers for 
targeting the cells214. Simple conjugation or coupling with DC 12 could be possible 
but a high concentration was required for endosomal escape. In general, the main 
limitation of the aptamer used as a delivery vehicle is the endosomal pathway215. In 
this study, DC 12 conjugated antagomir 125a-5p was used to delivery antagomir 
125a-5p to human baseline macrophages. The binding and transfection of 
conjugates have shown that both domains of conjugates are functional. DC 12 after 
conjugation recognized and bound to the cells and antagomir 125a-5p was able to 
bind to the endogenous miRNA 125a-5p via transfection. However, DC 12 guided 
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uptake limited the release of antagomir 125a-5p into the cytoplasm and could be 
entrapped in the endosomes.  
 
5.2   Immunogenicity of aptamer targeting immune cells 
Nucleic acid-based drug products are used in different novel treatment strategies for 
several medical conditions. These products range from single-stranded antisense 
oligonucleotides to complex ribozymes including aptamers216. Nucleic acid-based 
drug products are usually designed to act within a cell, a distinctive property different 
from conventional drugs216. Thus, the assessment of immunogenicity is usually 
essential for pharmacological agents used in treatment strategies. They may induce 
an immune response or the production of antibodies to the product that interferes 
with the mechanism of action or leads to unwanted side effects217. Oligonucleotides 
based therapeutics are structurally in close resemblance to the endogenous nucleic 
acids, particularly endogenous DNA, which could be surprisingly immunogenic once 
it has moved its usual nuclear location and is found in the bloodstream218. Therefore, 
DNA aptamers might stimulate an immune response when sensed by the DNA 
sensors. It usually depends on the physicochemical properties and protein 
association of the DNA. TLR 9 is the most prominent internal DNA sensor, which 
stimulates an immune response216. 
 
In the present study, the immunogenicity of DC 12 and D#23 aptamer was 
determined by the TNF-α HTRF assay (Figure 4.2.1). CpG ODNs and LPS, 
considered to stimulate the immune response, have been used as positive controls. 
The concentration of TNF-α was measured from the supernatant of the treated cells. 
In general, nucleic acid ligands were sensed by the internal DNA sensors such as 
TLR3, 7/8, 9 or 13219 and signal cascades were activated for secretion of TNF-α. 
LPS and CpG ODNs induced a strong TNF-α secretion even in a minute amount but 
DC 12 and D#23 showed very low to no secretion even at a very high concentration 
(Figure 4.2.1). Consequently, these aptamers did not appear to be immunogenic.  
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These results are consistent with previous studies by Haßel101 and Fülle et al.220. 
Both studies used the TNF-α HTRF assay to investigate the immunogenicity of the 
aptamers and showed that aptamers were non-immunogenic.  
Thus, it provided strong evidence that these aptamers can be used to target immune 
cells in therapeutic and diagnostic applications without activating the immune 
response.  
 
However, in vivo information on the toxicity and immunogenicity of aptamers is very 
limited221. Introduction of unnatural nucleotides may cause serious chemical adverse 
effects or become immunogenic. LNA-modified nucleic acids cause severe 
hepatotoxicity in animal models222. To date, adverse events are very rare in the 
clinical evaluation of aptamers but may arise from continuous or repeated 
administration of aptamer therapeutics, polyanionic effects, intensive chemical 
modification, non-specific immune activation or unexpected tissue accumulation223-
225. Potential hepatotoxicity often results from the non-specific liver uptake of highly 
lipophilic molecules226.  
 
5.3   Characterization of DC 12 aptamer 
The native properties of aptamers as targeting molecules enable them to be used as 
a delivery vehicle for therapeutic agents. The structures of aptamers are easily 
predictable and can be modified by chemical modifications. These chemically 
modified aptamers can be easily linked to the cargo molecules for the development 
of diagnostic or therapeutic tools227. Several studies have shown that aptamers are 
promising molecules for targeting tumor cells when used as a delivery vehicle for 
small molecules such as siRNA, proteins, and drugs, even though the 
microvasculature of the tumor227,228.  
 
In the present study, the DC 12 aptamer structure was predicted using mfold191 
(Figure 4.2.2A), it is 80 nucleotides in length (Table 6-8). The DC 12 variant with 53 
nucleotides was generated and termed as DC 12.53. DC 12.53 retained the parental 
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loop and stem in the structure prediction (Figure 4.2.2B). DC 12.53 was able to 
recognize and bind to J774A.1 (Figure 4.2.5), THP-1 (Figure 4.2.6), human primary 
macrophages (Figure 4.2.12), and TPP macrophages (Figure 4.2.13). The 
scramble of DC 12.53 showed no binding and no recognition property.  DC 12.53 
was used in this study for the targeted delivery of antigen to DCs for CD8 T cell 
activation (Figure 4.5.2 and Figure S 9.3.1). Previously, two aptamers from the BM-
DCs cell-SELEX without truncation were used to activate T cells101.  The truncated 
aptamers are less expensive than the full-length aptamers. They are easy to 
synthesize with the solid phase synthesis of DNA with high yield.  
 
The other factor, which may influence the binding of the aptamer is the coupling or 
conjugation of the molecules at the 5‘ or 3‘ end. In this study, ATTO 647-N (red 
absorbing fluorophore) was conjugated at the 5‘ and 3‘ ends of the aptamers DC 12 
and DC 12.53. The conjugation of the fluorophore at either the 5‘ or 3‘ end of the 
aptamers showed that the aptamers retained the binding properties with the cells 
(Figure 4.2.7 and Figure 4.2.8). DC 12 was also synthesized with an extra 28 
nucleotides through solid phase synthesis, which showed that it bound to the cells in 
a competition binding assay (Figure S 9.2.1). These characterization studies 
provided a clue that DC 12 and DC 12.53 could be used as a delivery vehicle for the 
delivery of the small molecules. Cargo molecules can be conjugated to either ends 
of the aptamers. In the present study, DC 12 and DC 12.53 were further 
characterized regarding their uptake and internalization. Upon binding these 
aptamers were taken up by the cells and successfully internalized into the cells 
(Figure 4.2.9 and Figure 4.2.14).  
 
The G-quadruplex is another important structure frequently seen in ssDNA 
aptamers192. In the current study, CD spectroscopy revealed that DC 12 and DC 
12.53 could be folded into parallel G-quadruplex in the presence of ions (Figure 
4.2.3). Several experimental techniques are normally used to observe G-quadruplex 
such as atomic force microscopy, electron microscopy, sedimentation velocity 
analysis, UV melting etc but CD spectroscopy is considered to be a comprehensive 
Discussion 
87 
 
technique to observe G-quadruplex topology192. Further investigation will be needed 
to understand the G-quadruplex of DC 12 and DC 12.53. This could help in the 
therapeutic and diagnostic applications and even contributes to the natural 
biochemistry of G-rich nucleic acids192. The aptamer structure usually consists of 
stems, loops, and bulges but G-quadruplex structures often act as a motif to 
recognize the target as seen in many aptamers229. G-quadruplexes structure is one 
of the secondary structures to form well-defined tertiary structures of aptamers.  
Thus, it often increases the specific binding of aptamers and acts as a binding 
motif229. The secondary structures e.g., G-quadruplexes, T-junctions, bulges, 
pseudoknots, hairpins or their combinations forms a well-defined binding shapes. 
These shapes facilitate and enhance the binding properties through electrostatic 
interactions, π-π stacking interactions, and hydrogen bonds among aptamers and 
their targets. The structural properties of aptamers including G-quadruplexes help 
to elucidate patterns, principles, and diversity related to nucleic acids structural 
design, molecular recognition, and the adaptive binding behaviors229,230.  
 
5.4   Targeted delivery of aptamer-conjugates 
5.4.1   Aptamer-targeted inhibition of miRNA 125a-5p 
Aptamer-based targeted delivery and the amount of cargo that can reach 
successfully to the cytoplasm depends primarily on the following factors: The 
number of targeted protein on the cell surface, the ability to escape from the 
endosomal compartment, and the endocytic pathway215.  In the study at hand, 
aptamer-targeted inhibition of miRNA 125a-5p was studied. DC 12 aptamiR 125a-5p 
had both the aptamer and antagomir domains functional. DC 12 aptamer domain 
was able to recognize and bind to the cells (Figure 4.4.3). Antagomir 125a-5p 
domain was able to inhibit the endogenous miRNA 125a-5p via transfection in the 
stable cell line (Figure 4.4.4 and Figure 4.4.5). The DC 12 guided uptake of the 
aptamiR 125a-5p showed no interaction or inhibition of the miRNA 125a-5p (Figure 
4.4.6). It could be possible that the endocytic pathway for internalization of DC 12 
aptamer ends up in the endosomes or lysosomes. This could have limited the 
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delivery efficiency of the aptamer and antagomir 125a-5p would not have been able 
to interact with the endogenous miRNA 125a-5p in the cytoplasm. Thus, diminishes 
the inhibitory activity of antagomir 125a-5p. Normally, the aptamer-based delivery 
system internalizes through an endocytic mechanism and gets entrapped in the 
endosomes215. However, it has often been observed that the delivery efficiency, 
usually required for therapeutic activity by aptamer guided uptake was limited and 
far from optimal yet28.  
Thiel et al.231 selected an RNA aptamer through ‗cell-internalization SELEX‘ to 
deliver siRNA into the cells of interest. Aptamer-siRNA chimeras have been 
internalized and released into the cytoplasm through receptor-mediated 
internalization. The chimera was able to interact with the RNAi machinery in the 
cytoplasm. However, they did not know the uptake kinetics or the pharmacological 
mechanisms by which these aptamer-siRNAs chimeras usually escape from the 
endosomes231. Cell-internalization SELEX strategy could be used to identify aptamer 
targeting macrophages to efficiently deliver antagomir 125a-5p into the cytoplasm. 
However, in the current study, the characterization of DC 12 aptamer provided 
strong reasons for using it as a delivery vehicle. Antagomir 125a-5p was conjugated 
at the 3‘ end of the DC 12 aptamer and it may also be possible to use the free end of 
the aptamer or antagomir 125a-5p for endosomal escape purposes.  These ends 
can be used for the introduction or conjugation of certain protein tags232, peptides233, 
polyethyleneimine234, and nanoparticles235 to facilitate the endosomal escape. These 
agents act through proton sponge effect and cause disruption or lysis of the 
endosomes232. 
 
Furthermore, the treatment of TPP macrophages with DC 12 aptamiR 125a-5p did 
not show any alteration in the surface marker analysis (Figure 4.4.7). 500 nM 
aptamiR 125a-5p were incubated with the human baseline macrophages for 30 
minutes and the medium was replaced with the fresh medium containing TPP 
stimulants for the next three days. The surface marker analysis showed no 
difference when compared to untreated cells. Relatively low concentration of 
aptamiR 125a-5p (500 nM) was used to prevent the non-specific binding and cellular 
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uptake of the non-internalizing oligonucleotides, which tend to internalize at relatively 
high concentrations of ≥1.0 µM236,237. 
These results indicated that further characterization of DC 12 aptamer was required 
for endosomal escape strategies. It would also be possible to use a protein or 
peptide with the aptamiR 125a-5p to facilitate endosomal escape. The 5-8 µM 
concentration of the aptamiR might have an inhibitory effect23 or may change the 
endocytotic pathway of aptamer guided uptake.  
 
5.4.2   Aptamer-targeted delivery of OT-I peptide for CD8 T 
cells activation 
T-cell receptors (TCRs) are expressed by CD8 T cells that are activated by binding 
to the peptide bound to MHC class I molecules in a highly sensitive manner. These 
peptide ligands are degraded products of the endogenous polypeptide and are 
loaded on MHC I molecule in most cells. Upon recognition of the peptide, the T cell 
is activated and leads to the eradication of the target cell238. DCs are capable of 
proficiently presenting the ingested antigens to MHC I molecules. This process is 
known as cross-presentation and plays a significant role in the development of an 
immune response239. 
In the study at hand, DC 12.53 aptamer was used for the targeted delivery of OT-I 
peptide to DCs for CD8 T cell activation. The results showed that DC 12.53 was 
effective in delivering OT-I peptide and derived strong CD8 T cell activation (Figure 
4.5.2 and Figure S 9.3.1). As discussed in the previous section (Section 5.4.1), that 
aptamiR 125a-5p was entrapped in the endosomes, resulting in limited therapeutic 
efficiency, and provided evidence that aptamers were co-localized in the endosomal 
compartments. Therefore, aptamer-targeted delivery of OT-I peptide was also 
endocytosed, processed in these compartments, and loaded on MHC I molecule 
through cross-presentation to derive strong CD8 T cell activation. 
These results are consistent with Haßel101, where they used DNA aptamer D#7 (80 
nucleotides) for targeted activation of T cell with OVA peptide. In another study, 
DEC-205 RNA aptamer was selected which binds specifically to DEC205, which is 
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mainly expressed by DCs. DEC-205 aptamer conjugated with OVA has the 
capability to trigger T cell activation240. These studies and the study at hand shows 
that aptamer-based vaccine design for targeted delivery of the antigen can be a 
promising alternative to protein-based targeting strategies. Cell-targeting aptamers 
also have several advantages over antibodies as described in the previous section 
(Section 3.1.3).  
 
5.5   Perspective for future research 
The study at hand showed that aptamers have the potential to replace protein-based 
targeting approaches and be used as a delivery vehicle. Nevertheless, questions 
remain open for antagomir 125a-5p delivery. 
 
If the high concentration (5-10 µM) of DC 12 aptamiR 125a-5p is able to reach the 
cytoplasm? In the previous work, 5 µM concentration of aptamiR-21 was required to 
inhibit the endogenous miRNA-2128. By increasing the concentration, it may be 
possible to inhibit miRNA, but conditions still need to be optimized by selecting new 
aptamers for macrophages or by facilitating endosomal escape.  
 
Which chemical modification for antagomir could be used to inhibit miRNA 
efficiently? The most promising modifications to inhibit endogenous miRNAs are 
2‘O-methyl and LNA. LNA has some advantages over 2‘O-methyl modification. Tiny 
LNA (8 nucleotides) complementary to the seed region of miRNA is capable of 
inhibiting the target miRNA and miRNA family sharing the same seed region181. 
 
Which endosomal escape facilitating agent can be used to delivery aptamiR 125a-5p 
efficiently into the cytoplasm? What other pharmaceutical formulations can be 
developed using these aptamers as targeting domain with endosomal escape 
properties? AptamiR 125a-5p may be combined or formulated with endosomal 
escape facilitating agents such as protein tags232, peptides233, polyethyleneimine234, 
and nanoparticles235 to facilitate the endosomal escape or rupture of the endosome 
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in order to release the cargo into the cytoplasm. However, these agents need to be 
characterized in terms of toxicity and immune response for clinical use. 
 
What are the optimal conditions for inhibiting the endogenous miRNA 125a-5p 
through aptamiR 125a-5p in TPP macrophages? AptamiR 125a-5p can be 
administered during or after differentiation of human baseline macrophages into TPP 
macrophages. The treatment duration and time of administration are also critical 
parameters during the development of the therapeutics. Therefore, different optimal 
treatment conditions have to be determined, which have the maximum inhibitory 
effect on the endogenous miRNA 125a-5p. 
 
What is the role of these aptamers targeting THP-1 cells in basic and applied 
research in the immunological context? Are these aptamers capable of helping 
immunologists to use THP-1 cells for their research? DC 12 aptamer can be 
combined with drugs to further study the effect of targeted-drug delivery on 
monocytes or macrophages. DC 12 aptamer can be used as transfection agent for 
THP-1 cells, which are considered to be difficult to be transfected using non-viral 
approaches201. 
 
For in vivo use, further characterization of aptamer-based delivery of antigen to DCs 
will be required.  
 
5.6   Concluding remarks 
The study at hand demonstrates that aptamers have the potential to be used as a 
carrier molecules and provides a basis for further investigation of endosomal escape 
of aptamiR chimera for the reprogramming of macrophages. 
DC 12 aptamer was characterized from the NGS data of the previously performed 
BM-DCs cell-SELEX. DC 12 and DC 12.53 aptamers are valuable tools for our 
understanding of aptamers as a delivery vehicle. Selected aptamers are limited to 
delivering cargo into the cytoplasm. The reason for this is the endocytic pathway of 
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aptamer, which ends up in the endosomes and lysosomes. It could be improved by 
the use of different endosomal escape facilitating agents or design of special 
pharmaceutical formulations with aptamer as a targeting domain. 
These results were further verified by delivering the antigen through aptamer into the 
endosomes (processing compartments) for efficient presentation of antigen and CD8 
T cell activation. These aptamers contribute to the field of aptamer-based DC 
vaccines for potent T cell activation. In general, aptamers can be used as a delivery 
vehicle and are promising molecules as an alternative to protein-based targeting 
approaches. The doors are still open for improvement in this field, in order to 
regulate the pathway of internalization and endosomal escape of cell-targeting 
aptamers. 
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6   Materials 
6.1   Equipment 
Table 6-1 Equipment 
Equipment Manufacturer 
FACS Canto II BD 
Genoplex UV transilluminator VWR 
HPLC 1260 series, C18 Eclipse column Agilent 
JASCO J-810 CD spectrometer Jasco 
Liquid scintillation counter WinSpectral 1414 Perkin Elmer 
LSM 710 confocal laser scanning microscopy Zeiss 
MACS multistand Miltenyi Biotec 
Magnetic separator Miltenyi Biotec 
Nanodrop 2000c Spectrophotometer Thermo Scientific 
PCR Mastercycler personal Eppendorf 
Phosphorimager FLA-3000 Fujifilm 
Pipets Eppendorf 
Water purification system TKA/Thermo Scientific 
 
 
6.2   Consumables 
Table 6-2 Consumables 
Consumable Supplier 
Amicon Ultra-0.5 Centrifugal Filter Devices 10 K Millipore 
Cell culture plates Sarstedt; TPP; Greiner Bio One 
FACS tubes, 5 ml, 12 mm Sarstedt 
Falcon cell strainer 40 μm Sarstedt 
G25 Columns GE Healthcare 
LS Columns Miltenyi Biotec 
Nunclon culture plates Thermo Scientific  
Pre-separation filters (30 µM) Miltenyi Biotec 
Reaction tubes Sarstedt;Eppendorf 
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6.3   Commercially available kits 
Table 6-3 Commercially available kits 
Kit Supplier 
NucleoSpin Extract II Gel and PCR Clean-up Macherey and Nagel 
NucleoSpin plasmid Macherey and Nagel 
 
6.4   Cell culture 
Table 6-4 Cell culture 
 
6.5   Antibodies 
Table 6-5 Antibodies 
Antibody Manufacturer 
PE anti Human CD25 Biolegend 
Pacific Blue anti Human CD14 Biolegend 
APC anti Human CD86 Biolegend 
FITC anti Human CD23 Biolegend 
CD14 Positive Selection Microbeads, Human Milteny Biotech 
 
Cell culture Manufacturer 
Fetal bovine serum Sigma Aldrich 
Geneticin G418 ThermoFisher 
Gibco PBS 1x ThermoFisher 
Gibco RPMI 1640 ThermoFisher 
Gibco DMEM ThermoFisher 
Gibco 0.05% Trypsin/EDTA ThermoFisher 
Human pancoll, density 1.077g/ml Pan Biotech 
Lipofectamine 2000 ThermoFisher 
VLE-RPMI 1640 (Very Low Endotoxin) Liquid medium 
with stable glutamine 
Merck 
Penicillin [10000 U/ml]/Streptomycin [10 mg/ml] PAA 
Cyroprotective medium Lonza 
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6.6   Cytokines 
Table 6-6 Cytokines 
Cytokine Manufacturer 
TLR2 Ligand (Pam3CSK4) InvivoGen 
rh human GM-CSF ImmunoTools 
IFN gamma Immuno Tools 
rh IL-4 Immuno Tools 
rh TNF –alpha Immuno Tools 
Prostaglandin  E2 Sigma Aldrich 
 
6.7   Chemicals and reagents 
Table 6-7 Chemicals and reagents 
Reagent Supplier 
1,4-Dithiothreitol (DTT) Roth 
4‘,6-diamidino-2-phenylindole (DAPI) Sigma Aldrich 
Acetic acid Merck 
Acetonitril Fluka 
Agar Sigma Aldrich 
Agarose Merck; Genaxxon 
Ammoniumperoxodisulfate (APS) Roth 
Bis-Acrylamid, Rotiphorese Roth 
Bovine serum albumin (BSA, nuclease and protease free) Calbiochem 
Bromophenol blue Merck 
DNA ladders Fermentas;Thermo Scientific 
dNTPs/NTPs Larova 
DPBS Gibco 
Ethanol abs. Sigma Aldrich 
Ethdiumbromide Roth 
Ethylendiamintetraacetic acid (EDTA) AppliChem 
Fluorogel mounting medium EMS 
Formaldehyde Fluka 
ɣ-32P-ATP Perkin Elmer 
Isopropanol Merck 
Magnesium chloride-hexahydrate AppliChem 
N,N,N‘,N‘-tetramethylethylendiamide (TEMED) Roth 
Phenol Roth 
Potassium chloride (KCl) Gruessing 
Rotiphorese sequencing gel concentrate Roth 
Pwo polymerase Genaxxon 
Sodium chloride (NaCl) AppliChem 
Sodium dodecylsulfate (SDS) Roth 
Sodium acetate Gruessing 
T4 polynucleotide kinase (PNK) NEB 
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Taq polymerase In house production; Promega 
Tricine Roth 
Triethylamine (TEA) Sigma Aldrich 
Triethylammonium acetat (TEAA) Sigma Aldrich 
Tris Roth 
Triton-X 100 Merck 
Trypsin [0.05%]/EDTA [0.5M] Thermo Scientific 
Wheat germ agglutinin-Alexa Fluor 488 Invitrogen 
 
6.8   Oligonucleotides 
Table 6-8 Oligonucleotides 
Name Sequence 5’-3’ 
Ctrl 2 GCTGTGTGACTCCTGCAAGTGGTGTTAAGAGGTGAGGTATAACGCGGAATGG
TGCGAGGCGCAGCTGTATCTTGTCTCC 
D#23 GCTGTGTGACTCCTGCAACGTGGGCGGGTTTATATTTGGTGGTGGTGGGG 
GTGGTACTGTTGCAGCTGTATCTTGTCTCC 
DC 4 GCTGTGTGACTCCTGCAAGGGGAGGTGGGTGGGTTGGCCTTCACGTTATC 
TTTTGGTGGTTGCAGCTGTATCTTGTCTCC 
DC 6 GCTGTGTGACTCCTGCAACCAGGGGAGGATGGGAGGGTTTTTTTCGGATT 
CTTGTCGTGCTGCAGCTGTATCTTGTCTCC 
DC 7 GCTGTGTGACTCCTGCAACGTGGTATGTGGTGGGTGGTGGGGTGGTAGTT 
GGGTGGACGGTGCAGCTGTATCTTGTCTCC 
DC 8 GCTGTGTGCTCCTGCAACAGGGGAGGTGGGTGATTGGGTTGTTTTTCGCGGA
CGTGAGGTGCAGCTGTATCTTGTCTCC 
DC 10 GCTGTGTGACTCCTGCAACGAGTTTCTGAGGGTGGGTGGGTGGTTATTAGTC
GAGGTTGCAGCAGCTGTATCTTGTCTCC 
DC 12 GCTGTGTGACTCCTGCAACCAGGGTGGGATGGGTATTTTGAGGTGGAGGTGG
GGGTTGGTTGCAGCTGTATCTTGTCTCC 
DC 13 GCTGTGTGACTCCTGCAAGGGTGTTGTGGGGTGGGGCGGTGGGTGTGAGTG
TCGGCAGCTGGCAGCTGTATCTTGTCTCC 
DC 14 GCTGTGTGACTCCTGCAATGTGGTTCGGTAGGTCGGGGAGGGTGGTGGGTTA
TGCGGCGGGGCAGCTGTATCTTGTCTCC 
DC 15 GCTGTGTGACTCCTGCAACACAGGGGAGGTCGGGCGGGTTGTCTGCTTTCTT
GGGTCGGTTGCAGCTGTATCTTGTCTCC 
DC 20 GCTGTGTGACTCCTGCAACGTACTTTCACACGGGGAGGTGGGTTGGGTTCTG
ATTAGGGTTGCAGCTGTATCTTGTCTCC 
DC 21 GCTGTGTGACTCCTGCAACTGGGTCGGGGGTATTGTTTGCGATATGGGGGGT
TTTGGGGTGGCAGCTGTATCTTGTCTCC 
DC 12.53 CTGCAACCAGGGTGGGATGGGTATTTTGAGGTGGAGGTGGGGGTTGGTTGCA
G 
DC 12.53sc1 GGCGGTAGGGAGTGAGGTGGAGTGGCTTGTGAGGTCCGTGATAGCGTTTAG
GT 
DC 12.53sc2 GAACTCAAGACCCGGAGTTCCATTTCGAGTGAAGACTGTCGGAGTAGTGCATA 
 
miRNA 125a-
5p 
 
UCCCUGAGACCCUUUAACCUGUGA 
Antagomir 
125a-5p 
 
UCACAGGUUAAAGGGUCUCAGGGA 
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4X miRNA 
125a-5p target 
site 
 
GACGAGCTGTACAAGTAAAGCGGCCGCCTAATCACAGGTTAAAGGGTCTCAG
GGACTAATCACAGGTTAAAGGGTCTCAGGGACTAATCACAGGTTAAAGGGTCT
CAGGGACTAATCACAGGTTAAAGGGTCTCAGGGACGACTCTAGATCATAATCA
GCCATACC 
Fwd primer 
target site 
 
 
GACGAGCTGTACAAGTAAAGCG 
Rev primer 
target site 
 
GGTATGGCTGATTATGATCTAGAGTCG 
 
6.9   Mouse strains 
Table 6-9 Mouse strains 
Mouse strains Description 
C57BL/6J Wildtype strain 
OTI Rag2
-/-
 C57/BL6 background, CD8 T cells express TCR specific for OVA257-264 
on MHC I, deficient in recombinant activating gene 2 (Rag2), therefore 
no endogenous TCR expression 
 
 
6.10   Proteins 
Table 6-10 Ovalbumin (OVA) peptides 
Protein Sequence (N-C) Supplier 
MHC I peptide (OVA257-264) SIINFEKL Tebu-Bio 
OT-I peptide VSGLEQLESIINFEKLTEWTSSNV Panatecs 
 
6.11   Buffers and solutions 
6.11.1   Gel electrophoresis 
1 x TBE 
90 mM Tris pH 8.0, 90 mM Borat, 2 mM EDTA 
 
1 x DNA loading buffer 
25 mM Tris pH 8.0, 25 % glycerol, 25 mM EDTA, bromophenol blue 
 
1 x RNA loading buffer 
50 % formamide, 0.013 % SDS, 0.25 mM EDTA, bromophenol blue 
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10 x PAA loading buffer 
60 % formamide, 5 % SDS, 0.25 mM EDTA, bromphenol blue 
 
6.11.2   Binding assay 
Wash Buffer 
DPBS, 1 mM MgCl2, 1 mM CaCl2 
 
6.11.3   Isolation of CD14+ cells and staining 
MACS buffer 
1L DPBS, 2mM EDTA, 5ml FCS 
 
6.11.4   Bacteria culture 
Agar plates w/ kanamycin 
7.6 g Agar, 10 g LB broth, 500 ml ddH2O, 50 μl 100 mg/ml Kanamycin 
 
LB medium w/ kanamycin 
10 g LB broth, 500 ml ddH2O, 50 μl 100 mg/ml Kanamycin 
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7   Methods 
7.1   Working with nucleic acids 
7.1.1   Synthesis and storage of nucleic acids 
All nucleic acids have been purchased from ELLA-Biotech GmbH. They were 
dissolved in ddH20 as described in the manufacturer certificate of analysis. All 
oligonucleotides have been stored at -20°C.  
 
7.1.2   Quality control and concentration measurement  
The concentration of nucleic acids was determined by nanodrop 2000. The required 
size of the oligonucleotides and the quality was checked by agarose gel 
electrophoresis.  
The ATTO 647N-labeled DNA concentration was also determined by nanodrop 2000 
using the micro-array option. The labeling efficiency was determined by gel 
electrophoresis and the fluorescence was analyzed by Phosphorimager FLA-3000 
(Fujifilm). 
 
7.1.3   Agarose gel electrophoresis 
Usually, 4% agarose gels were used to monitor purchased nucleic acids, PCR 
products and 1% agarose gels were used for plasmid DNA.  For this, agarose 
powder was dissolved in 1 x TBE buffer and boiled in a microwave for several 
minutes. 4 µl of ethidiumbromide has been added to 40 ml of this solution which is 
1:10000 dilutions. This solution was thoroughly mixed and poured into the gel cast. 
The nucleic acid samples were diluted in a DNA or RNA loading buffer, 2 x RNA 
loading buffer was used for ssDNA and heated to 65°C for 5 minutes to prevent the 
secondary structures. The diluted samples were loaded into the gel wells. The gel 
was run for 15-20 minutes in the presence of 1 x TBE buffer at 130 V. The samples 
were run towards the positive charge and separated on the basis of their size. The 
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UV transilluminator (Genoplex, VWR) was used to visualize the separate 
oligonucleotides and the band size was determined by comparison with the DNA 
ladder. 
 
7.1.4   Polyacrylamide gel electrophoresis (PAGE) 
PAGE gel was used to analyze the labeling efficiency of radioactive labeled nucleic 
acids (32P). The receipt of the gel (10%) was described in Table 7-1 and was poured 
between the two glass plates of the chamber. The gel was stored for at least 45-60 
minutes for polymerization. After polymerization, the glass plates were carefully 
adjusted in the running chamber and filled with 1 x TBE buffer. The gel was pre-run 
at 370 V for 30 minutes. After pre-run, the wells of the gel were rinsed with 1 x TBE 
buffer using the syringe. Nucleic acid samples were diluted in PAA loading buffer 
and heated at 95°C for 3 minutes. The gel was run for approximately 1 hour at 370 
V. 
Table 7-1 Recipe for one PAGE gel 
Solution Volume (10%) Volume (15%) 
Rotiphorese sequencing gel concentrate 28 ml 42 ml 
8.3 M Urea 35 ml 21 ml 
8.3 M Urea in 10 x TBE   7 ml  07 ml 
TEMED 28  μl 28  μl 
10 % APS 560 μl 560 μl 
 
7.1.5   Thiol-maleimide conjugation 
The 5‘-maleimide antagomir 125a-5p and 3‘-thiol-C6 oligonucleotides were 
purchased from Ella-Biotech, dissolved in ddH20 as indicated in the certificate of 
analysis to obtain a final concentration of 100 µM. 
The concentration required for coupling of antagomir 125a-5p and oligonucleotide 
was calculated. The required concentration was aliquot in a clean screw cap vial and 
freeze-dried overnight using a freeze dryer.  Then next day, 2 ml of anhydrous 
acetonitrile (Acros Organics) was added to the vial. A screw cap with a hole was 
used and a septum was placed. The center of the septum was pierce with a 16 
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gauge needle, at a slight angle. The vial was placed in a 100 ml round bottom glass 
flask and connected to the schlenk line. The schlenk line provides the possibility of 
vacuum and dry argon flashing. Vacuum was gently increased to avoid bumping. 
Wait until the anhydrous acetonitrile has completely evaporated. The vacuum was 
released by dry argon. Then, 2 ml of anhydrous toluene (Acros Organics) was added 
to the vial via 16-gauge needle and completely evaporated, by increasing the 
vacuum. Electromagnetic hot plate was used to maintain temperature at 37°C with a 
sand bath. A further 2 ml of anhydrous toluene was added and evaporated again. 
The residue of the antagomir 125a-5p was visible after the evaporation.  The vial 
was removed from the flask. Again, 2 ml of anhydrous toluene was added and a 16-
gauge needle was removed from the vial.  The vial was placed in the sand bath at 
90°C for four hours. The vial was cooled at room temperature for 15 minutes and the 
16-gauge needle was inserted again. Anhydrous toluene was evaporated and the 
residue was dissolved in DPBS. The antagomir 125a-5p was ready for conjugation 
with the 3‘-thiol-C6 oligonucleotides.  
The 3‘-thiol-C6 oligonucleotides were reduced with 1:2000 DTT, 100 mM DTT was 
freshly prepared in 1 M TEAA pH 8.3 - 8.5. The oligonucleotides with DTT were 
heated at 70°C for 3 minutes and incubated at room temperature for 1 hour. 
Reduced oligonucleotides were desalted with the aid of 10 K Amicon column into 
ddH20.  
Subsequently, reduced oligonucleotides were mixed with a 5 times molar excess of 
maleimide antagomir 125a-5p. The mixture was incubated at 4°C for 24 hours and 
then loaded into 4% agarose gel to confirm reaction between thiol and maleimide 
oligonucleotides.  
Similarly, for the conjugation of N-maleimide peptide with 5‘-thiol-C6 
oligonucleotides, thiol-C6 oligonucleotides were reduced as mentioned above and 
incubated with a 40-fold molar excess of N-maleimide peptide. Subsequently, the 
mixture was incubated at 4°C, overnight. The conjugates were purified via RP-HPLC 
on a C18 column with a linear gradient of 10 mM TEA and 100 Mm HFIP. The 
concentration was measured using nanodrop 2000 and analyzed by LC-MS.  
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7.1.6   Purification of aptamer-antagomir conjugates 
For the purification of aptamer-antagomir conjugates (aptamiR), 15% PAGE gel was 
prepared. The gel was pre-run at 175 V for 15 minutes. Aptamer-conjugates were 
carefully mixed with the 2:1 loading buffer.  Samples were mixed, then centrifuged. 
After cleaning the wells, the samples were loaded into the wells with 1 x TBE buffer. 
The gel was run at 175 V for about 1.5-2 hours until the loading buffer had reached 
more than 2/3 of the gel. The gel was wrapped in the plastic wrap to visualize 
separation of the bands. Separated bands were visualized with UV-light at 254 nm, 
using a fluorescent TLC plate (TLC Silica gel 60 F254) under the wrapped gel. The 
upper band was marked by drawing a box around, under the UV light. The gel was 
carefully cut with a plastic wrap using a sterile scalpel. After removing the plastic 
wrap, the gel pieces were transferred into the 2 ml reaction tube. The bands were 
crushed into small pieces with a blue pipette tip.   0.3 M sodium acetate pH 5.4 was 
also added to the reaction tube, so that the crushed gel pieces could move freely.  
The reaction tube was placed in the thermomixer at 65°C for a minimum of 1.5 
hours.  Then, the supernatant was filtered to remove the gel pieces using a 5 ml 
syringe filled with glass wool. The gel pieces in the reaction tube were washed twice 
with 100 µl of 0.3 M sodium acetate pH 5.4. Absolute ethanol was pre-cooled at -
20°C and added to the sample volume three times. For better precipitation of the 
conjugates, 1 µl of glycogen has been added. Samples were incubated at -80°C for 
15 minutes and, centrifuged at 4°C at 21130 xg for 45 minutes. The supernatant was 
discarded and the pellet was washed with 100 µl of 70% ethanol. The samples were 
centrifuged at 21130 xg for 10 minutes at room temperature. The supernatant was 
discarded again. The pellet was air-dried under the hood and was resuspended with 
ddH2O. Conjugates concentration was measured using the nanodrop 2000 ssDNA 
option. 
 
7.1.7   Polymerase chain reaction (PCR) 
For the amplification of the 4X miRNA 125a-5p target site that was later inserted into 
the EGFP reporter gene, the pipetting scheme and program are shown below. 
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Table 7-2 Pipetting scheme for amplication of target site  
Reagent  Stock concentration Volume (µl)       Final 
Pwo reaction buffer 10 x 10 1x 
dNTPs 25 mM each 0.8 0.2 mM 
miRNA 125a-5p fwd 100 µM 1 1 µM 
miRNA 125a-5p rev 100 µM 1 1 µM 
Pwo polymerase 2.5 U/µl 2.5 5 U 
DNA template   1-10 nM 
ddH20  Q.S=50 µl  
Q.S= quantity sufficient 
Table 7-3 PCR program for amplication of target site  
Step Time (min) Temperature (°C) 
Activation of Pwo (first cycle) 5 95 
Denaturation 1 95 
Annealing 1.5 57 
Elongation 1.5 72 
Final elongation (after last cycle ) 3 72 
Storage ∞ 4 
 
Restriction enzymes were used to make sticky ends of the PCR product for cloning. 
After restriction digestion, nucleospin clean-up kit from Machery and Nagel was used 
to purify the product. 
 
7.1.8   
32
P- labeling of ssDNA 
The ssDNA was labeled with 32P at the 5‘ end using the enzyme T4 polynucleotide 
kinase (PNK) for a radioactive binding assay. All reagents (Table 7-4) were mixed 
and incubated at 37°C for 1 hour. The mixture was then desalted using G25 column.  
Table 7-4 PCR program for amplication of target site  
Reagent Stock concentration Volume (µl) Final 
T4 PNK reaction 
buffer 
10 x 2 1 x 
ɣ-32P-ATP 10 μCi/μl 1 10 μCi 
ssDNA 1 μM 10 10 pmol 
T4 PNK 10 U/μl 2 20 U 
ddH20 -- 5 -- 
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7.2   Working with bacteria and bacterial plasmids 
7.2.1   Preparation of antibiotic stock solution 
50 mg/ml Kanamycin antibiotic stock solution in ddH20 was prepared for LB and LB 
agar plates. The antibiotic stock solution was aliquoted and stored at -20°C. 
 
7.2.2   LB medium and agar plates 
For agar plates, 7.6 g agar and 10 g LB broth were mixed with 500 ml deionized 
water and autoclaved at 121°C for 15 minutes. After cooling the solution at room 
temperature, 50 μl Kanamycin antibiotic stock solution was added in 500 ml at a final 
concentration of 50 μg/ml. The solution was poured into the petri dishes. The plates 
had been stored at 4°C. 
LB medium was prepared by mixing 10 g LB broth with 500 ml deionized water and 
then autoclaved. The solution has been stored at room temperature. All procedures 
have been performed under sterile conditions to prevent contamination. The 
bacterial culture hood was used for the preparation of agar plates. 
 
7.2.3   Transformation of E.coli (Competent cells) 
Competent cells were used for transformation of E. coli with EGFP-4X miRNA 125a-
5p plasmid. For this purpose, cells were thawed on the ice for 4-5 minutes. 50 ng/µl 
plasmid DNA or ligated plasmid with the reporter gene was added to 50 µl 
competent cells. The cells had been incubated on the ice for 30 minutes. Then, the 
cells were exposed to a heat shock at 42°C for 90 sec. 450 µl ice-cold LB medium 
was added and the cells were incubated at 37°C at 800 rpm for 1 hour. The mixture 
was then plated on LB-kanamycin agar plates and incubated at 37°C overnight.  The 
next day, bacterial colonies were picked and placed overnight in the LB medium for 
plasmid isolation. 
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7.2.4   Liquid bacterial culture  
For the preparation of glycerol stock and isolation of plasmid, 25 ml autoclaved LB 
medium with 25 µl kanamycin was mixed in 50 ml falcon under sterile condition. One 
bacterial colony from the LB-kanamycin agar plate was picked with the help of a 
yellow pipette tip and placed in the falcon. The falcon was placed in the shaking 
incubator at 37°C and at 150 rpm overnight.   
 
7.2.5   Preparation of bacterial glycerol stock 
For long term storage of bacteria, 500 µl of the liquid bacterial culture was mixed 
with 500 µl of 50% glycerol in a 2 ml screw reaction tube and gently mixed. The 
reaction tubes were then transferred to the -80°C freezer.  
 
7.2.6   Isolation of plasmid from liquid bacterial culture 
Plasmids were isolated from the liquid bacterial culture using the Nucleospin 
Plasmid kit from Machery and Nagel according to the manufacturer‘s protocol.  
 
7.2.7   Construction of the reporter gene plasmid 
5‘-
TCACAGGTTAAAGGGTCTCAGGGACTAATCACAGGTTAAAGGGTCTCAGGGAC
TAATCACAGGTTAAAGGGTCTCAGGGACTAATCACAGGTTAAAGGGTCTCAGG
GA-3‘ target sites have been cloned in the 3‘UTR of the pEGFP-N1 plasmid. Briefly, 
the control pEGFP-N1plasmid was cut using two restriction enzymes NotI and XbaI.  
4X miRNA 125a-5p target sites were amplified with these restriction sites. The 
amplified PCR product was subjected to double digestion with these enzymes to 
produce the sticky ends (Table 7-5). Then, the linearized plasmid and the PCR 
products with sticky ends were then ligated (1:3) overnight using NEB ligation 
protocol. Transformation into E.coli was performed the following day and was plated 
on the agar plates containing kanamycin antibiotic for the selection of positive 
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colonies. The liquid culture was prepared with a positive colonies and the plasmid 
was purified. The purified plasmid was sent to the Sanger sequencing for 
confirmation of the 4X miRNA 125a-5p target site at the 3‘UTR of pEGFP-N1. 
Table 7-5 Pipetting scheme for double restriction digestion  
Reagents Plasmid  volume (µl) PCR insert Volume (µl) 
Restriction Buffer Neb 3.1 2 2 
Acetylated BSA 10 µg/µl 0.2 0.2 
DNA 1 µg 8.7 8.7 
Mix by pipetting 
NotI 0.5 0.5 
Xbal 0.5 0.5 
Sterile ddH2O Upto 20 Upto 20 
*Incubate at 37°C for 1 hour. Heat inactivation at 65°C for 15 minutes 
 
Table 7-6 Pipetting scheme for ligation reaction 
Reagents Volume (µl) 
T4 DNA ligase buffer (10X) 2 
Linearized plasmid  4 
PCR insert 16 
Nuclease free water 1.5 
T4 DNA ligase 1.5 
*Incubate at 17°C overnight. Next day, Heat inactivation at 65°C for 10 minutes 
 
7.3   Working with mice and cells 
7.3.1   Mice 
OTI RAG2-/- and C57BL/6J mice have been used in this study. Animals were bred, 
maintained, and nourished in the central animal facility of the LIMES Institute at the 
University of Bonn under a specific pathogen-free environment. All experimental 
procedures and protocols were used in accordance with the local animal guidelines. 
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7.3.2   Cell culture 
All the cell lines and primary cells were handled under a sterile hood using sterile 
devices and materials. Cells were grown under normal cell culture conditions (37°C, 
5% CO2, 95% humidity). Mycoplasma PCR (Minerva Biolabs) was performed for all 
cell lines every three months to determine mycoplasma contamination. Cell lines 
were cultivated for a maximum period of two months and then replaced by a new 
culture.  
 
7.3.3   Cell lines 
THP-1 cells (human monocytes) and J774A.1 cells (mouse macrophages) were 
kindly provided by Prof. Dr. Albert Haas of the University of Bonn, Germany. THP-1 
cells were cultured in RPMI 1640 while J774A.1 cells were cultured in DMEM, high 
glucose, GlutaMAXTM (ThermoFischer) supplemented with fetal bovine serum 
(Sigma) 10% at 37°C. THP-1 and J774A.1 cells were maintained in culture by 
routine passage every 2-3 days and cultivated for a maximum period of two months.  
 
7.3.4   Isolation and cultivation of bone marrow-dervied 
dendritic cells 
After isolation and cultivation, BM-DCs were kindly provided by Dr. Silvana Haβel 
(AK Mayer) and Dr. Maria Embgenbroich (AK Burgdorf), LIMES Institute Bonn. In 
brief, wildtype mice were sacrificed to extract the femur and the tibia. The bone 
cavity was flushed with PBS and the bone marrow cells were filtered through a 40 
µm nylon membrane. Cells have been cultivated in DC-medium for 7 days. After 3-4 
days, the medium was changed. 
 
7.3.5   Isolation and differentiation of human macrophages  
Buffy coats were obtained from the University of Bonn Hospital. IL4, IFN-ɤ, and TPP 
macrophages were isolated and cultured as described above109. In brief, Buffy coat 
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was cut with scissors on one of the two hoses. Blood was collected in the T175 flask 
and diluted with DPBS at 1:1. Four falcons were prepared with 35 ml of diluted 
blood. The pipette was filled with 14 ml ficoll (at room temperature) and the pipette 
was carefully placed touching the bottom of the falcon. The final volume of each 
falcon was 49 ml. The density gradient centrifugation was then performed at room 
temperature for 25 minutes with 615 xg without brake and 9 acceleration. Carefully, 
the top serum layer had been discarded. The white blood cell ring fraction was 
carefully transferred to a new 50 ml falcon tube. The volume was adjusted to 50 ml 
with DPBS and the falcon tubes were rotated 2 x at 200 xg for 10 minutes at room 
temperature (thrombocyte wash). The supernatant was discarded and the cell pellet 
was resuspended at a defined volume of MACS buffer or DPBS (20 ml). Cells were 
counted with dilution of 1:40 (5 μl cell suspension + 195 μl trypan blue). The cell 
pellet was resuspended in 80 µl per 107 cells of MACS buffer (count and calculate- 
about 1.5 to 3 ml), 200 μl of MACS CD14 microbeads were added, well mixed and 
incubated in the fridge (4°C) for 15 minutes. The cells have been resuspended with 
25 ml MACS buffer. The cells were centrifuged at 6°C for 8 minutes at 300 xg. At the 
same time, columns have been prepared using 1 LS column per donor.  The 
MidiMACS-Magnet was placed in the cell culture hood and washed to equilibrate the 
column with 3 ml of the MACS buffer. 30 μm presorting filter was placed on the LS-
column and a 50 ml falcon was placed under the LS-column to collect the CD14- cell 
fractions. After centrifugation, the supernatant was discarded, and the cell pellet was 
resuspended in 3 ml MACS buffer. On the separation filter, 3 x 1ml of the suspended 
cells were filtered.  3 ml of the MACS buffer was added on the remaining cells in the 
50 ml falcon to suspend the remaining cells and applied to the filter. The column was 
washed with 3 ml fresh MACS buffer and the filter was discarded before the final 
washing step. The column was removed from the magnetic separator for the elution 
of CD14+ cells. The column was placed on an appropriate collection tube prefilled 
with 10 ml DPBS, pipette 5 ml of MACS buffer onto the column and CD14+ cells 
were flushed using the plunger. Then the volume was adjusted up to 50 ml with 
DPBS. The cells were counted with appropriate dilution with trypan blue (20 μl cell 
suspension + 80 μl trypan blue). 
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Monocytes were seeded with the density of 2x106 cells/ml in 6 well NUNC plates (2 
ml/well) with VLE RPMI 1640 medium supplemented with 10% FCS. The 
differentiated scheme has been described in (Table 7-7). 
 
After d3, the cells were observed under the microscopy. The cells were scraped and 
counted. The cells were spun down to 6 minutes at 1200 rpm to discard the old 
media. The cells were seeded in 6 well NUNC plates (2 ml/well) with VLE RPMI 
1640 medium supplemented with 10% FCS and GM-CSF 500 U/ml plus the 
stimulants described in Table7-7.  
Table7-7 Differentiation to the baseline macrophages d0 to d3 
Cell Phenotype Cell number Stimulants  VLE RPMI 1640 medium+ 
10% FCS and GM-CSF 
500U/ml 
Baseline 
macrophages 
2x10
6
 cells/ml GM-CSF 500U/ml 
d3 to d6 differentiation 
IL-4 2x10
6
 cells/ml rh IL-4  :1000 U/ml GM-CSF 500U/ml VLE 
RPMI 1640 medium+ 
10% FCS and GM-CSF 
500U/ml 
IFN-ɤ 2x10
6
 cells/ml IFN      : 200 U/ml 
TPP 2x10
6
 cells/ml TNFα     :800U/ml 
PGE2       :1μg/ml 
Pam3     :1μg/ml 
 
 
7.3.6   Surface markers analysis of differentiated 
macrophages 
The plates (Section 7.3.5) were taken out from the incubator, stored at room 
temperature for 5 minutes and the media was allowed to cool down. The 
supernatant was pipetted out into a 15 ml falcon and stored on the ice. 1 ml of 2 mM 
EDTA in DPBS (room temperature) was immediately pipetted to the cells that 
remained adherent. After 10 minutes, the cells were checked. They were still 
attached to the plate, but they were round and contracted. The cells were carefully 
resuspended by pipetting them with 1 ml pipette 3-5 times. The cell fraction was 
combined with the previous one and stored on the ice. Immediately 2 ml cold DPBS 
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was added to the remaining cells of the plate and carefully scraped. The scrap cell 
fractions have been combined and stored on ice. The plate was washed with cold 
DPBS once or twice. All fractions were combined and the falcon was centrifuged at 
4°C for 5 minutes at 280 to 300 xg. The supernatant was discarded and the cell 
pellet was carefully resuspended in the MACS buffer. The cells suspension was 
adjusted according to the protocol 1x106 cells/ml in the MACS buffer. In the four 
FACS tubes, 100 µl of cells suspension was added. The stained and unstained 
samples proceeded in a parallel manner/fashion. The unspecific antibody binding 
was blocked by the MACS buffer at 4°C for 20 minutes. The antibody mixture was 
prepared as described in Table 7-8. 
Table 7-8 Pipeting scheme for antibody mixture 
     
 
 
The cells were stained with an antibody mixture in the fridge for 30 minutes. The cell 
suspension was washed with 2 ml cold DPBS and centrifuged at 300 xg. The 
supernatant was discarded and the pellet was resuspended in 200 µl DPBS. 
 
Five FACS tubes were prepared with the compensation beads with 100 µl of MACS 
buffer. 0.5 µl of each antibody was added. They were also incubated in the fridge for 
30 minutes. 
 
Antibody 1X 
CD14 0.1 µl 
CD23 0.5 µl 
CD25 0.1 µl 
CD86 0.1 µl 
Mix =0.8 µl 
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7.3.7   Cells binding assays 
7.3.7.1   Radioactive binding assay using the Cherenkov 
protocol 
J774A.1 cells were seeded at a density of 0.5x105 in 24 well plates one day before 
the Cherenkov assay. On the day of the binding assay, the cells were washed with 
wash buffer (DPBS, 1 mM MgCl2, 1 mM CaCl2) and then incubated with 1 pmol 
32P-
DNA in 500 µl cells growth medium (DMEM, 10% FCS) for 10 minutes at 37°C. 
4x1.5 ml reaction tubes/well was prepared with 500 µl ddH20. After the incubation 
time, the supernatant was collected in a 1.5 ml reaction tube (fraction I). The cells 
were washed twice with 500 μl wash buffer and collected in a 1.5 ml reaction tube 
(fractions II and III) each time.  The cells were carefully detached in the presence of 
trypsin/EDTA and collected in a 1.5 ml reaction tube (fraction IV). The Cherenkov 
protocol was used to measure the radioactivity of all the fractions in Liquid 
scintillation counter WinSpectral (Perkin Elmer). 
The percentage of bound 1 pmol 32P-DNA was calculated using the following 
formula: 
% 𝑏𝑜𝑢𝑛𝑑 𝐷𝑁𝐴 =   
𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐼𝑉
𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐼 + 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐼𝐼 + 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐼𝐼𝐼 + 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐼𝑉
 ∗ 100 
 
7.3.7.2   Flow cytometry binding assay 
THP-1 cells were counted and resuspended at a density of 4x105 in the FACS tubes. 
The cells were incubated with ATTO 647N-labeled aptamers diluted in 100 μl cells 
growth medium (RPMI 1640, 10% FCS) for 10 minutes at 37°C and 5% CO2. Then 2 
ml wash buffer (DPBS, 1 mM MgCl2, 1 mM CaCl2) was added to the FACS tubes. 
The FACS tubes were centrifuged at 200 xg for 5 minutes and the supernatant was 
discarded. The cell pellet was resuspended with 1 ml wash buffer and then 
centrifuged. Approximately 800 μl supernatant was discarded and the remaining 
buffer was used to measure the percentage of cells bound by DNA. The percentage 
of cells bound by DNA was measured by BD FACS Canto II and the results were 
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analyzed by FlowJo software (BD). The binding assay for human baseline 
macrophages and TPP macrophages were done as explained above for THP-1 
cells. 
 
Binding assay for J774A.1 cells was also done as explained above for THP-1 cells, 
except that 2x105 J774A.1 cells were counted and seeded in 24-well plates one day 
before the binding assay. On the day of binding assay, cells were washed twice with 
500 µl wash buffer. The cells were then incubated with ATTO 647N-labeled 
aptamers diluted in 200 μl cells growth medium (DMEM, 10%FCS) for 10 minutes at 
37°C and 5% CO2. The cells were scraped and transferred into the FACS tubes 
containing 2 ml wash buffer. The FACS tubes were centrifuged at 200 xg for 5 
minutes and the supernatant was discarded. The cell pellet was resuspended with 1 
ml wash buffer and then centrifuged again. Approximately 800 μl supernatant was 
discarded and the remaining buffer with the cells was used to find the percentage of 
cells bound by the DNA. The percentage of cells bound by the DNA was measured 
by BD FACS Canto II and the results were analyzed by the FlowJo software (BD). 
 
The aptamiR 125a-5p binding was determined through a competition binding assay. 
8x104 THP-1 cells were counted and resuspended in the FACS tubes. The cells 
were incubated with 50 nM ATTO 647N-labeled aptamers in the presence and 
absence of 400 nM competitors at 37°C for 10 minutes. The cells were washed and 
analyzed as stated above for THP-1. 
 
7.3.8   Confocal microscopy 
2x105 cells were counted and seeded onto coverslips. Coverslips were cleaned with 
absolute ethanol and dried before being placed in a 12-well plate. Cells have been 
incubated for one day under standard cell culture conditions. Next day, the cells 
were washed with wash buffer (DPBS, 1 mM MgCl2, 1 mM CaCl2) and followed by 
incubation with 250 nM ATTO 647N-labeled DC12, DC 12.53 and their respective 
controls at 37°C for 10 minutes. The cells were washed three times with wash buffer 
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and subsequently washed once with 1 ml DPBS. Then the cells were fixed by using 
4% paraformaldehyde diluted in DPBS at 4°C for 30 minutes. The cells were then 
washed thrice with DPBS and the membranes were stained with WGA-Alexa fluor 
488 (100 µg/ml in 500 μl DPBS) for 10 minutes. The cells were washed again thrice 
and finally, the nuclei were stained with 1:1000 (1 mg/ml) DAPI in DPBS for 5 
minutes and washed thrice with DPBS, once with 2 ml ddH2O. The coverslips were 
carefully mounted onto the slides with the fluorogel mounting medium. The slides 
were placed in the dark overnight at room temperature and on following day 
microscopy data of the slides were acquired using LSM 710 confocal laser scanning 
microscopy (Zeiss).  
 
7.3.9   Cell transfection 
7.3.9.1   Transient transfection of reporter gene plasmid 
with miRNA 125a-5p mimic and control mimic 
J774A.1 cells were transiently transfected with 500 ng of the control pEGFP-N1 
plasmid (CP) and EGFP-4X 125a-5p plasmid (4X 125a-5p) with different 
concentration of miRNA 125a-5p mimic (miRNA 125a-5p mimic, Sigma-Aldrich) and 
control miRNA mimic (miRNA negative control 1, Sigma-Aldrich). Briefly, 1x105 cells 
were plated one day before the transfection in 24-well plate. On the day of the 
transfection, two reaction mixtures were prepared separately and mixed together.  
Mixture A: 500 ng CP and 4X 125a-5p plasmids with the different concentrations of 
miRNA mimic and control mimic were diluted in Opti-MEM, respectively.  
Mixture B: In a second reaction tube, the same volume of Opti-MEM was 
supplemented with 1.5 μl lipofectamine 2000 (transfection agent) and incubated at 
room temperature for 5 minutes.  
Then mixture A and mixture B were mixed and incubated for another 20 minutes 
according to the manufacturer protocol. The cells were washed with DPBS once and 
replaced with fresh medium. After the incubation period, the mixture was slowly 
transferred into wells for 24 hours. After 24 hours, the cells were scraped and 
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washed with 1 ml DPBS in the FACS tubes. The supernatant was discarded and the 
MFI of the cells (1x105 cells) was measured in flow cytometry using FITC-A channel 
for the EGFP. 
 
7.3.10   Generation of stable cell line J774A.1 miRNA 125a-
5p 
7.3.10.1   Stable transfection of EGFP-4X 125a-5p plasmid 
Stable cell line J774A.1 miRNA 125a-5p was generated with permanent integration 
of the EGFP-4X 125a-5p plasmid. For that 2 µg of the plasmid was transiently 
transfected with lipofectamine 2000 according to the manufacturer protocol as 
described in the transient transfection section above (Section 7.3.9.1). After 2 days, 
the positive cells selection of EGFP-4X 125a-5p plasmid was started by adding 300 
µg/ml G418 to the cell culture medium. After four weeks of the positive selection, the 
surviving cells were used for the isolation of monoclonal cell lines. As a control, 
EGFP plasmid without target sites has also been transiently transfected as for 
EGFP-4X 125a-5p plasmid. 
 
7.3.10.2   Isolation of monoclonal cells 
Surviving cells from the stable transfected EGFP-4X 125a-5p plasmid (Section 
7.3.10.1) showed fluorescence compared to untransfected J774A.1 cells. Cell 
sorting was performed using a flow cytometer with cell sorting function (BD FACS-
Aria, Flow cytometry core facility, University of Bonn). The cells were individually 
placed on a 96-well plate for both the control and the EGFP-4X 125a-5p plasmid. 
96-well plates were placed in an incubator with standard cell culture conditions for 
two weeks. After two weeks, each well was observed under a fluorescence 
microscopy for cell growth and cell fluorescence. Cells that grew in monolayer with 
80-90% confluency and had fluorescence were transferred into 24-well plates. Then 
these cells were placed in T25 flask when they showed 80-90% confluency in 12-
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well and 6-well plates. These cells were maintained in the culture with DMEM, 10% 
FCS and 300 µg/ml G418. They were cultivated for a period of not more than 2 
months and with a passage after every 2-3 days.    
 
7.3.11   Transfection of the stable cell line J774A.1 miRNA 
125a-5p with antagomir 125a-5p  
Stable cell line J774A.1 miRNA 125a-5p cells and control stable cell line were 
transfected with different concentrations of antagomir 125a-5p (Ella-Biotech) and 
control antagomir (Ella-Biotech). Briefly, 4x104 cells were plated in a 24-well plate 
one day before the transfection. On the day of the transfection, two reaction mixtures 
were prepared separately and then mixed together.  
Mixture A: Different concentrations of antagomir 125a-5p and control antagomir 
were diluted in Opti-MEM, respectively.  
Mixture B: In a second reaction tube, the same volume of Opti-MEM was 
supplemented with 1.5 μl lipofectamine 2000 (transfection agent) and incubated for 5 
minutes.  
 
Then, mixture A and mixture B were mixed and incubated for another 20 minutes 
according to the manufacturer protocol. The cells were washed once with DPBS and 
replaced with 300 µl Opti-MEM.  After the incubation period, the mixture was slowly 
transferred into the wells for 4 hours. After 4 hours, the Opti-MEM was replaced with 
fresh medium (DMEM, 10% FCS) for the next 48 hours. The cells were scraped and 
washed with 1 ml DPBS in FACS tubes. The supernatant was discarded and the 
MFI of the cells was measured in the flow cytometry using the FITC-A channel for 
the EGFP. 
 
In aptamiR 125a-5p transfection, 50 nM concentration of the aptamiR was prepared 
in a manner similar to mixture A preparation. 
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7.3.12   Antagomir and peptide delivery assays 
7.3.12.1   Aptamer-targeted delivery of antagomir 125a-5p  
Stable cell line J774A.1 miRNA 125a-5p cells were treated with aptamiR 125a-5p. 
Briefly, 4x104cells were plated in a 24-well plate one day before treatment. On the 
day of treatment, the cells were washed once with DPBS and replaced with 200 µl 
DMEM medium containing 10% FCS and 500 nM aptamiR 125a-5p for four hours. 
Subsequently, the medium was replaced with fresh medium (DMEM, 10% FCS) for 
the next 48 hours. The cells were scraped and washed with 1 ml DPBS in FACS 
tubes. The supernatant was discarded and the MFI of the cells was measured in 
flow cytometry using the FITC-A channel for EGFP. As a positive control, cells were 
transfected as described in Section 7.3.11 for aptamiR 125a-5p.  
For human baseline macrophage treatment, CD14+ monocytes have been 
differentiated into human baseline macrophages as described in Section 7.3.5. After 
3 days, 4x106 cells were counted and treated with aptamiR 125a-5p, control 
aptamers for 30 minutes. Then, the medium was replaced by fresh medium 
containing TPP stimulants. As a positive control, untreated cells, IL-4, and IFN-ɤ 
macrophages have also been differentiated for the next three days (Section 7.3.5). 
After 72 hours, the profiles of the cell surface markers were determined through flow 
cytometry as described in Section 7.3.6. 
 
7.3.12.2   In vitro proliferation assay 
Dr. Silvana Haβel (AK Mayer), University of Bonn, Germany, performed In vitro 
proliferation assay. Briefly, 5x104 BM-DCs were counted and seeded in 96-well 
plates and incubated for one hour under standard cell culture conditions. OT-I T cells 
(OVA-specific CD8 T cells) have been isolated from spleen and incubated with 1 µM 
CFSE in PBS at 37°C for 15 minutes. The T cells were washed thrice with cold PBS 
at 4°C and centrifuged. In the meantime, MHC I peptide, aptamer-peptide 
conjugates, and OT-I peptides were diluted in DC-medium and added to the BM-
DCs, incubated at 37°C for 10 minutes. Subsequently, the supernatants from BM-
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DCs were removed and 1x105 OT-I T cells in 100 µl T cell medium was added. Cells 
were incubated for 24 hours. After 24 hours, 200 µl T cell medium was added per 
well and incubated for another 48 hours. The T cells were stained with an anti-CD8 
alpha antibody conjugated with fluorophore and analyzed with flow cytometry. The 
anti-CD8 antibody was diluted 1:400 in the FACS buffer supplemented with mouse 
serum 1:100. 
 
7.3.13   Statistical Analysis   
The flow cytometry data was analyzed using FlowJo software (TreeStar, USA). All 
results were presented as mean ± SD, as described in tables and figures legends 
using GraphPad prism 5 (GraphPad Software, San Diego, USA).  
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9   Supplementary data 
9.1   Binding of DC 12.53 to BM-DCs 
Table 9-1: % BM-DCs bound by ATTO 647N-labeled aptamers and MFI in flow cytometry 
binding assay 
Aptamer % Cells bound  MFI 
Ctrl 2 11.5±1.56 1.0±0.01 
DC 12 63.6±0.21 9.1±4.08 
DC 12.53 57.7±4.95 11.8±3.7 
DC 12.53sc1 9.54±0.02 1.0±0.04 
 
Figure S 9.1.1: ATTO 647N-labeled aptamers binds to BM-DCs in flow cytometry binding 
assay4×10
5
 BM-DCs were incubated with 250nM of 5‘-ATTO 647N-labeled aptamers at 37°C for 10 
minutes. The percentage cells bound with aptamers were measured by flow cytometry.(n=1, mean ± 
SD). 
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9.2   Binding of DC 12ext to THP-1 cells 
Table 9-2: % THP-1 cells bound by ATTO 647N-labeled aptamers and relative MFI in flow 
cytometry compeition binding assay 
Aptamer % Cells bound  Relative MFI (aptamer/control) 
Ctrl 2* 6.12±0.47 1.00±0.02 
 
 
DC 12+ 
 
No competition 80.6±6.85 2.40±0.32 
1:2 DC 12ext 61.6±14.7 2.13±0.43 
1:4 DC 12ext 43.5±3.41 1.77±0.18 
1:8 DC 12ext 26.3±7.30 1.74±0.25 
1:8 Ctrl 2 ext 68.4±14.6 2.51±0.21 
 *control 
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Figure S 9.2.1: Competition binding assay for 28 nucleotide extended DC 12 
(A) Mfold predicted secondary structure of DC 12 and (B) 28 nucleotide extended DC 12 (DC 12ext). 
(C) 250 nM ATTO-647 N labeled DC 12 was co-incubated with an increasing concentration of DC 
12ext with THP-1 cells and binding was analyzed by flow cytometry (n=2, mean ± SD). 
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9.3   Aptamer-targeted delivery of OT-I peptide for CD8 T 
cells activation 
 
Figure S 9.3.1: Aptamer-targeted delivery of OT-I peptide for CD8 T cells activation 
1×10
5 
OVA-CD8 specific T cells were stained with fluorescent staining dye (CFSE) and incubated 
with 5×10
4
 BM-DCs treated with 100 nM of aptamer-conjugates, OT-I peptide and 1 nM of MHC I 
peptide. The ranged gate percentage of CFSE T cell proliferation of triplicates (mean ± SD) was 
plotted (n=1 in triplicates).The assay was performed by Dr.SilvanaHaβel. 
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10   Abbreviations 
2‘-O-Me 2‘-O-Methyl 
2‘-O-MOE 2‘-O-methoxyethyl 
AGO Argonaute 
ASO antisense oligonucleotides 
APCs Antigen presenting cells 
APS Ammoniumperoxodisulfate 
BM-DC Bone marrow-derived dendritic cell 
BSA Bovine serum albumin 
CD Cluster of differentiation  
cDCs conventional/classical DCs 
CDP Common DC precursor 
CFSE Carboxyfluoresceine succinimidyl ester 
CLEC-1 C-type lectin receptor-1 
CMV cytomegalovirus 
CTLs Cytotoxic T-lymphocyte 
CTLA-4 CTL-associated protein 4 
CLRs C-type lectin-like receptors 
Ctrl 2 Control DNA sequence 2 
DAMP Damage-associated molecular pattern 
DAPI 4‘,6-diamidino-2-phenylindole 
DC Dendritic cell 
DCIR DC immunoreceptor 
DC-SIGN DC-specific ICAM-3 grabbing non-integrin 
DEC-205 Dendritic and epithelial cells, 205 kDa 
Dectin DC-associated C-type lectin 
DLEC DC lectin 
DNA Deoxyribonucleic acid 
DTT 1,4-Dithiothreitol 
EDTA Ethylendiamintetraacetic acid 
EEA1 Early endosome antigen 1 
EGFP Enhanced green fluorescent protein 
ELISA Enzyme-linked immunosorbent assay 
FACS  fluorescence-activated cell sorter  
FDA Food and drug administration (USA) 
GM-CSF Granulocyte macrophage colony-stimulating factor 
H Human 
HFIP 1,1,1,3,3,3-hexafluoro-2-propanol 
HPLC High-performance liquid chromatography 
IFN Type I Interferons 
IFN-ɤ Interferon-gamma 
IL Interleukin 
LAMP-1 Lysosome-associated membrane glycoprotein 1 
LC-MS Liquid chromatography-mass spectrometry 
LNA Locked nucleic acid 
LPS Lipopolysaccharide 
M1 Classically activated macrophages 
M2 Alternatively activated macrophages 
M-CSF Macrophage colony-stimulating factor 
MDP Monocyte-dendritic cell precursor  
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MFI Mean fluorescence intensity 
MHC Major histocompatibility complex 
miRISC miRNA-mediated silencing complex 
miRNA MicroRNA 
MPS Mononuclear phagocyte system 
mRNA Messenger RNA 
MR Mannose receptor 
NGS Next generation sequencing 
NOD-like  Nucleotide-binding oligomerization domain-like receptors 
Nt nucleotides 
ODN Oligonucleotide 
OVA Ovalbumin 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cells  
PCR Polymerase chain reaction 
pDCs Plasmacytoid DCs 
PEG Polyethylene glycol 
PNK Polynucleotide kinase 
pre-miRNA Precursor miRNA 
pri-miRNA Primary RNA 
PRR Pattern recognition receptor 
PSMA Prostate-specific membrane antigen 
RISC RNA-induced silencing complex 
RNA Ribonucleic acid 
PKR Protein kinase R 
PS Phosphorothioate 
SD Standard deviation 
SDS Sodium dodecylsulfate 
SELEX Systematic evolution of ligands by exponential enrichment 
siRNA Small interfering RNA 
ssDNA Single stranded DNA 
STAT4 Signal Transducer And Activator Of Transcription 4 
TAMs Tumor associated macrophages 
TCR T cell receptor 
TEA Triethylamine 
TEAA Triethylammonium acetat 
TEMED N,N,N‘,N‘-tetramethylethylendiamide 
Th T helper cell 
TLR Toll-like receptor 
TNF-α Tumor necrosis factor α 
TPP Tumor necrosis factor, prostaglandin E2 and TLR2-ligand(Pam3CK) 
TRBP trans-activation response RNA-binding protein 
UTR Untranslated region 
WGA Wheat germ agglutinin 
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